https://trial.medpath.com/news/bioage-labs-faces-investor-lawsuit-after-obesity-drug-trial-halted-on-safety-concerns 2025-05-21T00:39:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioage-labs-faces-investor-lawsuit-after-obesity-drug-trial-halted-on-safety-concerns 2025-05-21T00:39:13+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-to-close-gene-therapy-manufacturing-facility-in-libertyville-illinois 2025-05-21T00:39:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bristol-myers-squibb-to-close-gene-therapy-manufacturing-facility-in-libertyville-illinois 2025-05-21T00:39:06+00:00 hourly 0.9 https://trial.medpath.com/news/env-101-shows-promising-results-in-idiopathic-pulmonary-fibrosis-treatment-reducing-pulmonary-vessel-volume 2025-05-21T00:38:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/env-101-shows-promising-results-in-idiopathic-pulmonary-fibrosis-treatment-reducing-pulmonary-vessel-volume 2025-05-21T00:38:05+00:00 hourly 0.9 https://trial.medpath.com/news/immediate-statin-therapy-reduces-cardiovascular-events-by-one-third-in-diabetes-patients 2025-05-21T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immediate-statin-therapy-reduces-cardiovascular-events-by-one-third-in-diabetes-patients 2025-05-21T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/network-meta-analysis-reveals-optimal-treatment-strategies-for-male-osteoporosis 2025-05-21T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/network-meta-analysis-reveals-optimal-treatment-strategies-for-male-osteoporosis 2025-05-21T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-advisory-committee-votes-6-2-in-favor-of-daratumumab-for-high-risk-smoldering-multiple-myeloma 2025-05-20T23:19:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-advisory-committee-votes-6-2-in-favor-of-daratumumab-for-high-risk-smoldering-multiple-myeloma 2025-05-20T23:19:28+00:00 hourly 0.9 https://trial.medpath.com/news/fda-advisory-committee-rejects-new-indications-for-genentech-s-columvi-and-pfizer-s-talzenna-combination 2025-05-20T23:19:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-advisory-committee-rejects-new-indications-for-genentech-s-columvi-and-pfizer-s-talzenna-combination 2025-05-20T23:19:27+00:00 hourly 0.9 https://trial.medpath.com/news/empower-cad-study-confirms-benefits-of-ivl-first-strategy-in-female-patients-with-calcified-coronary-lesions 2025-05-20T23:16:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/empower-cad-study-confirms-benefits-of-ivl-first-strategy-in-female-patients-with-calcified-coronary-lesions 2025-05-20T23:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/vantai-and-blueprint-medicines-expand-collaboration-to-tackle-undruggable-targets-with-ai-powered-proximity-therapeutics 2025-05-20T22:49:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vantai-and-blueprint-medicines-expand-collaboration-to-tackle-undruggable-targets-with-ai-powered-proximity-therapeutics 2025-05-20T22:49:40+00:00 hourly 0.9 https://trial.medpath.com/news/fresenius-kabi-launches-30-mg-30-ml-epinephrine-injection-for-emergency-care-and-septic-shock 2025-05-20T20:47:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fresenius-kabi-launches-30-mg-30-ml-epinephrine-injection-for-emergency-care-and-septic-shock 2025-05-20T20:47:00+00:00 hourly 0.9 https://trial.medpath.com/news/stemrim-expands-global-patent-portfolio-for-redasemtide-cartilage-regeneration-therapy 2025-05-20T20:45:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stemrim-expands-global-patent-portfolio-for-redasemtide-cartilage-regeneration-therapy 2025-05-20T20:45:34+00:00 hourly 0.9 https://trial.medpath.com/news/poolbeg-pharma-secures-ps4-1-million-fundraising-to-advance-clinical-programs-in-oncology-and-obesity 2025-05-20T20:44:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/poolbeg-pharma-secures-ps4-1-million-fundraising-to-advance-clinical-programs-in-oncology-and-obesity 2025-05-20T20:44:52+00:00 hourly 0.9 https://trial.medpath.com/news/poolbeg-pharma-launches-ps4-million-equity-raise-to-advance-cancer-and-obesity-drug-candidates 2025-05-20T20:44:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/poolbeg-pharma-launches-ps4-million-equity-raise-to-advance-cancer-and-obesity-drug-candidates 2025-05-20T20:44:27+00:00 hourly 0.9 https://trial.medpath.com/news/ccm-biosciences-to-present-breakthrough-4th-generation-egfr-inhibitors-for-nsclc-at-asco-2025 2025-05-20T20:43:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ccm-biosciences-to-present-breakthrough-4th-generation-egfr-inhibitors-for-nsclc-at-asco-2025 2025-05-20T20:43:48+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-warning-about-severe-itching-after-discontinuing-common-allergy-medications 2025-05-20T20:23:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-warning-about-severe-itching-after-discontinuing-common-allergy-medications 2025-05-20T20:23:32+00:00 hourly 0.9 https://trial.medpath.com/news/fda-advisory-committee-rejects-genentech-s-columvi-expansion-for-transplant-ineligible-dlbcl-patients 2025-05-20T20:22:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-advisory-committee-rejects-genentech-s-columvi-expansion-for-transplant-ineligible-dlbcl-patients 2025-05-20T20:22:36+00:00 hourly 0.9 https://trial.medpath.com/news/spider-venom-derived-peptide-shows-promise-in-post-prostatectomy-erectile-dysfunction-phase-ii-trial 2025-05-20T20:20:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spider-venom-derived-peptide-shows-promise-in-post-prostatectomy-erectile-dysfunction-phase-ii-trial 2025-05-20T20:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/brain-biotech-expands-european-footprint-with-full-acquisition-of-breatec-and-new-production-facility 2025-05-20T20:19:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brain-biotech-expands-european-footprint-with-full-acquisition-of-breatec-and-new-production-facility 2025-05-20T20:19:52+00:00 hourly 0.9 https://trial.medpath.com/news/spain-dramatically-reduces-timeframe-between-eu-drug-approval-and-reimbursement-decisions 2025-05-20T20:19:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spain-dramatically-reduces-timeframe-between-eu-drug-approval-and-reimbursement-decisions 2025-05-20T20:19:34+00:00 hourly 0.9 https://trial.medpath.com/news/glofitamab-gemox-shows-survival-benefit-in-phase-3-starglo-trial-for-r-r-dlbcl-but-fda-advisory-committee-questions-us-applicability 2025-05-20T20:19:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glofitamab-gemox-shows-survival-benefit-in-phase-3-starglo-trial-for-r-r-dlbcl-but-fda-advisory-committee-questions-us-applicability 2025-05-20T20:19:27+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-hyalex-orthopaedics-ide-supplement-for-pivotal-trial-of-freestyle-knee-implant 2025-05-20T20:17:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-hyalex-orthopaedics-ide-supplement-for-pivotal-trial-of-freestyle-knee-implant 2025-05-20T20:17:41+00:00 hourly 0.9 https://trial.medpath.com/news/tempus-and-verastem-partner-to-develop-companion-diagnostic-for-first-fda-approved-kras-mutant-lgsoc-treatment 2025-05-20T18:48:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tempus-and-verastem-partner-to-develop-companion-diagnostic-for-first-fda-approved-kras-mutant-lgsoc-treatment 2025-05-20T18:48:29+00:00 hourly 0.9 https://trial.medpath.com/news/cellprothera-partners-with-cellforcure-by-seqens-for-phase-3-manufacturing-of-heart-attack-cell-therapy 2025-05-20T18:45:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellprothera-partners-with-cellforcure-by-seqens-for-phase-3-manufacturing-of-heart-attack-cell-therapy 2025-05-20T18:45:50+00:00 hourly 0.9 https://trial.medpath.com/news/aging-impairs-car-t-cell-therapy-effectiveness-through-metabolic-decline-swiss-study-reveals 2025-05-20T18:19:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aging-impairs-car-t-cell-therapy-effectiveness-through-metabolic-decline-swiss-study-reveals 2025-05-20T18:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/tourmaline-bio-s-heart-disease-antibody-shows-promise-in-phase-2-but-shares-fall-amid-competition-concerns 2025-05-20T17:41:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tourmaline-bio-s-heart-disease-antibody-shows-promise-in-phase-2-but-shares-fall-amid-competition-concerns 2025-05-20T17:41:22+00:00 hourly 0.9 https://trial.medpath.com/news/finnish-researchers-develop-gene-signature-test-to-predict-cancer-immunotherapy-response 2025-05-20T17:17:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/finnish-researchers-develop-gene-signature-test-to-predict-cancer-immunotherapy-response 2025-05-20T17:17:23+00:00 hourly 0.9 https://trial.medpath.com/news/usc-spine-center-joins-pivotal-clarity-trial-to-evaluate-nociscan-for-chronic-low-back-pain 2025-05-20T16:38:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/usc-spine-center-joins-pivotal-clarity-trial-to-evaluate-nociscan-for-chronic-low-back-pain 2025-05-20T16:38:07+00:00 hourly 0.9 https://trial.medpath.com/news/more-impact-ag-secures-us-patent-for-needle-free-speedinject-technology 2025-05-20T16:37:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/more-impact-ag-secures-us-patent-for-needle-free-speedinject-technology 2025-05-20T16:37:00+00:00 hourly 0.9 https://trial.medpath.com/news/lymphodepletion-enhances-mar-t-cell-therapy-efficacy-in-lymphoma-patients-marker-therapeutics-reports 2025-05-20T16:36:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lymphodepletion-enhances-mar-t-cell-therapy-efficacy-in-lymphoma-patients-marker-therapeutics-reports 2025-05-20T16:36:53+00:00 hourly 0.9 https://trial.medpath.com/news/novel-baff-r-car-t-therapy-achieves-complete-response-in-heavily-pretreated-follicular-lymphoma-patient 2025-05-20T16:36:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-baff-r-car-t-therapy-achieves-complete-response-in-heavily-pretreated-follicular-lymphoma-patient 2025-05-20T16:36:51+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-poolbeg-pharma-s-polb-001-for-cancer-immunotherapy-induced-cytokine-release-syndrome 2025-05-20T16:36:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-designation-to-poolbeg-pharma-s-polb-001-for-cancer-immunotherapy-induced-cytokine-release-syndrome 2025-05-20T16:36:49+00:00 hourly 0.9 https://trial.medpath.com/news/kalivir-advances-novel-oncolytic-immunotherapy-vet3-tgi-in-phase-1-1b-trial-for-advanced-solid-tumors 2025-05-20T16:36:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kalivir-advances-novel-oncolytic-immunotherapy-vet3-tgi-in-phase-1-1b-trial-for-advanced-solid-tumors 2025-05-20T16:36:47+00:00 hourly 0.9 https://trial.medpath.com/news/pharmaessentia-s-ropeginterferon-shows-promising-results-in-phase-3-trial-for-essential-thrombocythemia 2025-05-20T16:28:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmaessentia-s-ropeginterferon-shows-promising-results-in-phase-3-trial-for-essential-thrombocythemia 2025-05-20T16:28:05+00:00 hourly 0.9 https://trial.medpath.com/news/eisai-to-present-long-term-leap-002-data-and-novel-pipeline-advances-at-asco-2025 2025-05-20T16:27:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eisai-to-present-long-term-leap-002-data-and-novel-pipeline-advances-at-asco-2025 2025-05-20T16:27:06+00:00 hourly 0.9 https://trial.medpath.com/news/actimed-therapeutics-launches-program-to-combat-muscle-loss-in-glp-1-treated-obesity-patients 2025-05-20T16:26:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/actimed-therapeutics-launches-program-to-combat-muscle-loss-in-glp-1-treated-obesity-patients 2025-05-20T16:26:53+00:00 hourly 0.9 https://trial.medpath.com/news/chop-researchers-develop-breakthrough-aav-vectors-for-brain-gene-therapy-at-lower-doses 2025-05-20T16:26:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chop-researchers-develop-breakthrough-aav-vectors-for-brain-gene-therapy-at-lower-doses 2025-05-20T16:26:46+00:00 hourly 0.9 https://trial.medpath.com/news/experimental-medication-shows-promise-in-treating-cocaine-addiction 2025-05-20T16:25:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/experimental-medication-shows-promise-in-treating-cocaine-addiction 2025-05-20T16:25:12+00:00 hourly 0.9 https://trial.medpath.com/news/philikos-initiates-phase-1-2-trial-of-t-guard-for-diffuse-cutaneous-systemic-sclerosis 2025-05-20T16:25:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/philikos-initiates-phase-1-2-trial-of-t-guard-for-diffuse-cutaneous-systemic-sclerosis 2025-05-20T16:25:03+00:00 hourly 0.9 https://trial.medpath.com/news/imec-unveils-revolutionary-miniaturized-ingestible-sensor-for-non-invasive-gut-health-monitoring 2025-05-20T16:24:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imec-unveils-revolutionary-miniaturized-ingestible-sensor-for-non-invasive-gut-health-monitoring 2025-05-20T16:24:56+00:00 hourly 0.9 https://trial.medpath.com/news/avicanna-sponsors-phase-ii-clinical-trial-to-evaluate-cannabis-extracts-for-osteoarthritis-pain 2025-05-20T16:22:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avicanna-sponsors-phase-ii-clinical-trial-to-evaluate-cannabis-extracts-for-osteoarthritis-pain 2025-05-20T16:22:55+00:00 hourly 0.9 https://trial.medpath.com/news/biostate-ai-secures-12m-series-a-to-revolutionize-rna-sequencing-and-molecular-diagnostics 2025-05-20T16:22:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biostate-ai-secures-12m-series-a-to-revolutionize-rna-sequencing-and-molecular-diagnostics 2025-05-20T16:22:03+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-and-regeneron-announce-aim4-trial-to-advance-personalized-asthma-treatment 2025-05-20T16:18:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-and-regeneron-announce-aim4-trial-to-advance-personalized-asthma-treatment 2025-05-20T16:18:55+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-first-ever-clearance-for-pediatric-functional-dyspepsia-treatment-to-neuraxis-s-ib-stim 2025-05-20T16:18:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-first-ever-clearance-for-pediatric-functional-dyspepsia-treatment-to-neuraxis-s-ib-stim 2025-05-20T16:18:53+00:00 hourly 0.9 https://trial.medpath.com/news/fda-greenlights-promontory-therapeutics-phase-3-trial-design-for-pt-112-in-metastatic-prostate-cancer 2025-05-20T16:18:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-greenlights-promontory-therapeutics-phase-3-trial-design-for-pt-112-in-metastatic-prostate-cancer 2025-05-20T16:18:16+00:00 hourly 0.9 https://trial.medpath.com/news/fda-overhauls-covid-19-vaccine-approval-process-limiting-access-for-healthy-adults-and-children 2025-05-20T16:18:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-overhauls-covid-19-vaccine-approval-process-limiting-access-for-healthy-adults-and-children 2025-05-20T16:18:07+00:00 hourly 0.9 https://trial.medpath.com/news/maipl-therapeutics-and-endosure-form-alliance-to-accelerate-non-hormonal-endometriosis-treatment-development 2025-05-20T16:17:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maipl-therapeutics-and-endosure-form-alliance-to-accelerate-non-hormonal-endometriosis-treatment-development 2025-05-20T16:17:58+00:00 hourly 0.9 https://trial.medpath.com/news/addf-invests-2-16-million-in-life-molecular-imaging-s-novel-pet-tracer-for-alzheimer-s-neuroinflammation 2025-05-20T16:17:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/addf-invests-2-16-million-in-life-molecular-imaging-s-novel-pet-tracer-for-alzheimer-s-neuroinflammation 2025-05-20T16:17:36+00:00 hourly 0.9 https://trial.medpath.com/news/act-technology-shows-promising-results-in-enhancing-chemotherapy-for-colorectal-liver-metastases 2025-05-20T15:45:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/act-technology-shows-promising-results-in-enhancing-chemotherapy-for-colorectal-liver-metastases 2025-05-20T15:45:22+00:00 hourly 0.9 https://trial.medpath.com/news/novel-aav-capsid-variant-shows-superior-gene-delivery-to-brain-regions-affected-by-huntington-s-and-parkinson-s 2025-05-20T15:44:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-aav-capsid-variant-shows-superior-gene-delivery-to-brain-regions-affected-by-huntington-s-and-parkinson-s 2025-05-20T15:44:53+00:00 hourly 0.9 https://trial.medpath.com/news/stryker-receives-fda-clearance-for-optablate-bvn-system-to-treat-chronic-lower-back-pain 2025-05-20T14:43:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stryker-receives-fda-clearance-for-optablate-bvn-system-to-treat-chronic-lower-back-pain 2025-05-20T14:43:43+00:00 hourly 0.9 https://trial.medpath.com/news/doron-therapeutics-advances-motys-for-knee-osteoarthritis-following-successful-fda-meeting 2025-05-20T12:44:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/doron-therapeutics-advances-motys-for-knee-osteoarthritis-following-successful-fda-meeting 2025-05-20T12:44:58+00:00 hourly 0.9 https://trial.medpath.com/news/minghui-pharmaceutical-initiates-phase-ii-trial-combining-pd-1xvegf-bispecific-with-trop-2-adc-for-advanced-nsclc 2025-05-20T12:44:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/minghui-pharmaceutical-initiates-phase-ii-trial-combining-pd-1xvegf-bispecific-with-trop-2-adc-for-advanced-nsclc 2025-05-20T12:44:35+00:00 hourly 0.9 https://trial.medpath.com/news/safety-concerns-emerge-for-gold-based-cisplatin-mimics-in-cancer-treatment-development 2025-05-20T12:43:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/safety-concerns-emerge-for-gold-based-cisplatin-mimics-in-cancer-treatment-development 2025-05-20T12:43:54+00:00 hourly 0.9 https://trial.medpath.com/news/fda-upgrades-xinnate-s-tcp-25-trial-for-epidermolysis-bullosa-to-registrational-status 2025-05-20T12:43:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-upgrades-xinnate-s-tcp-25-trial-for-epidermolysis-bullosa-to-registrational-status 2025-05-20T12:43:39+00:00 hourly 0.9 https://trial.medpath.com/news/merck-and-imec-partner-to-develop-advanced-microphysiological-systems-platform-for-drug-discovery 2025-05-20T12:11:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-and-imec-partner-to-develop-advanced-microphysiological-systems-platform-for-drug-discovery 2025-05-20T12:11:57+00:00 hourly 0.9 https://trial.medpath.com/news/enibarcimab-shows-promising-results-in-biomarker-guided-septic-shock-treatment 2025-05-20T12:11:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enibarcimab-shows-promising-results-in-biomarker-guided-septic-shock-treatment 2025-05-20T12:11:23+00:00 hourly 0.9 https://trial.medpath.com/news/pasithea-s-pas-004-outperforms-fda-approved-mek-inhibitor-in-preclinical-ibd-study 2025-05-20T12:10:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pasithea-s-pas-004-outperforms-fda-approved-mek-inhibitor-in-preclinical-ibd-study 2025-05-20T12:10:44+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-data-confirms-trikafta-s-long-term-efficacy-as-gold-standard-in-cystic-fibrosis-treatment 2025-05-20T12:10:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-data-confirms-trikafta-s-long-term-efficacy-as-gold-standard-in-cystic-fibrosis-treatment 2025-05-20T12:10:37+00:00 hourly 0.9 https://trial.medpath.com/news/novel-drug-combination-shows-promise-for-b-cell-acute-lymphoblastic-leukemia-with-reduced-toxicity 2025-05-20T12:10:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-drug-combination-shows-promise-for-b-cell-acute-lymphoblastic-leukemia-with-reduced-toxicity 2025-05-20T12:10:28+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-virginia-expands-manning-institute-of-biotechnology-with-66m-additional-contract 2025-05-20T12:09:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-of-virginia-expands-manning-institute-of-biotechnology-with-66m-additional-contract 2025-05-20T12:09:40+00:00 hourly 0.9 https://trial.medpath.com/news/bora-biologics-expands-san-diego-facility-with-2000l-bioreactor-capacity-to-meet-growing-cdmo-demand 2025-05-20T11:09:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bora-biologics-expands-san-diego-facility-with-2000l-bioreactor-capacity-to-meet-growing-cdmo-demand 2025-05-20T11:09:01+00:00 hourly 0.9 https://trial.medpath.com/news/nextcell-pharma-and-fujifilm-irvine-scientific-form-strategic-alliance-to-advance-msc-therapy-development 2025-05-20T10:12:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nextcell-pharma-and-fujifilm-irvine-scientific-form-strategic-alliance-to-advance-msc-therapy-development 2025-05-20T10:12:02+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-develops-novel-antibody-approaches-to-enable-aav-gene-therapy-redosing 2025-05-20T08:37:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regeneron-develops-novel-antibody-approaches-to-enable-aav-gene-therapy-redosing 2025-05-20T08:37:10+00:00 hourly 0.9 https://trial.medpath.com/news/veraxa-biotech-appoints-oncology-veteran-rick-austin-as-chief-scientific-officer-to-advance-novel-cancer-therapies 2025-05-20T08:36:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/veraxa-biotech-appoints-oncology-veteran-rick-austin-as-chief-scientific-officer-to-advance-novel-cancer-therapies 2025-05-20T08:36:12+00:00 hourly 0.9 https://trial.medpath.com/news/kancera-advances-cardiovascular-drug-pipeline-with-recardio-partnership-and-fda-engagement 2025-05-20T06:33:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kancera-advances-cardiovascular-drug-pipeline-with-recardio-partnership-and-fda-engagement 2025-05-20T06:33:50+00:00 hourly 0.9 https://trial.medpath.com/news/new-global-review-reveals-comprehensive-landscape-of-interstitial-cystitis-clinical-trials-in-2025 2025-05-20T04:42:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-global-review-reveals-comprehensive-landscape-of-interstitial-cystitis-clinical-trials-in-2025 2025-05-20T04:42:22+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-enters-6-billion-licensing-deal-with-china-s-3sbio-for-novel-cancer-drug 2025-05-20T04:42:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-enters-6-billion-licensing-deal-with-china-s-3sbio-for-novel-cancer-drug 2025-05-20T04:42:13+00:00 hourly 0.9 https://trial.medpath.com/news/gabapentin-shows-promise-in-extending-survival-for-glioblastoma-patients-mass-general-brigham-study-reveals 2025-05-20T04:42:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gabapentin-shows-promise-in-extending-survival-for-glioblastoma-patients-mass-general-brigham-study-reveals 2025-05-20T04:42:12+00:00 hourly 0.9 https://trial.medpath.com/news/nitrous-oxide-breakthrough-enables-safer-gene-therapy-delivery-to-brain 2025-05-20T04:42:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nitrous-oxide-breakthrough-enables-safer-gene-therapy-delivery-to-brain 2025-05-20T04:42:08+00:00 hourly 0.9 https://trial.medpath.com/news/biomed-x-and-boehringer-ingelheim-launch-initiative-to-revolutionize-retinal-drug-delivery 2025-05-20T04:15:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomed-x-and-boehringer-ingelheim-launch-initiative-to-revolutionize-retinal-drug-delivery 2025-05-20T04:15:38+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-teal-wand-first-at-home-hpv-self-collection-device-for-cervical-cancer-screening 2025-05-20T04:13:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-teal-wand-first-at-home-hpv-self-collection-device-for-cervical-cancer-screening 2025-05-20T04:13:51+00:00 hourly 0.9 https://trial.medpath.com/news/reunion-neuroscience-completes-patient-dosing-in-phase-2-reconnect-trial-of-re104-for-postpartum-depression 2025-05-20T02:43:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/reunion-neuroscience-completes-patient-dosing-in-phase-2-reconnect-trial-of-re104-for-postpartum-depression 2025-05-20T02:43:23+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-blood-test-for-alzheimer-s-diagnosis-boosting-roche-and-bioarctic-shares 2025-05-20T02:42:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-blood-test-for-alzheimer-s-diagnosis-boosting-roche-and-bioarctic-shares 2025-05-20T02:42:52+00:00 hourly 0.9 https://trial.medpath.com/news/new-guidelines-and-therapies-reshape-acne-treatment-approach-in-2025 2025-05-20T02:42:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-guidelines-and-therapies-reshape-acne-treatment-approach-in-2025 2025-05-20T02:42:00+00:00 hourly 0.9 https://trial.medpath.com/news/data-analysis-reveals-utilization-not-drug-prices-drives-340b-program-s-explosive-growth 2025-05-20T02:40:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/data-analysis-reveals-utilization-not-drug-prices-drives-340b-program-s-explosive-growth 2025-05-20T02:40:52+00:00 hourly 0.9 https://trial.medpath.com/news/stryker-receives-fda-clearance-for-optablate-bvn-system-to-treat-chronic-low-back-pain 2025-05-20T02:11:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stryker-receives-fda-clearance-for-optablate-bvn-system-to-treat-chronic-low-back-pain 2025-05-20T02:11:26+00:00 hourly 0.9 https://trial.medpath.com/news/fda-questions-pfizer-s-approach-to-expand-talzenna-s-indication-in-prostate-cancer 2025-05-20T02:11:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-questions-pfizer-s-approach-to-expand-talzenna-s-indication-in-prostate-cancer 2025-05-20T02:11:22+00:00 hourly 0.9 https://trial.medpath.com/news/regenxbio-secures-250-million-royalty-monetization-deal-to-advance-gene-therapy-pipeline 2025-05-20T02:11:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regenxbio-secures-250-million-royalty-monetization-deal-to-advance-gene-therapy-pipeline 2025-05-20T02:11:21+00:00 hourly 0.9 https://trial.medpath.com/news/meta-analysis-reveals-safety-differences-between-lecanemab-and-donanemab-in-early-alzheimer-s-disease-treatment 2025-05-20T00:44:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/meta-analysis-reveals-safety-differences-between-lecanemab-and-donanemab-in-early-alzheimer-s-disease-treatment 2025-05-20T00:44:44+00:00 hourly 0.9 https://trial.medpath.com/news/virtual-trial-shows-combination-rescue-inhaler-reduces-severe-asthma-attacks-by-nearly-50 2025-05-20T00:43:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/virtual-trial-shows-combination-rescue-inhaler-reduces-severe-asthma-attacks-by-nearly-50 2025-05-20T00:43:57+00:00 hourly 0.9 https://trial.medpath.com/news/fda-advisory-committee-rejects-pfizer-s-talzenna-expansion-for-broader-prostate-cancer-population 2025-05-20T00:43:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-advisory-committee-rejects-pfizer-s-talzenna-expansion-for-broader-prostate-cancer-population 2025-05-20T00:43:52+00:00 hourly 0.9 https://trial.medpath.com/news/be-biopharma-initiates-first-in-human-trial-of-crispr-based-gene-therapy-for-haemophilia-b 2025-05-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/be-biopharma-initiates-first-in-human-trial-of-crispr-based-gene-therapy-for-haemophilia-b 2025-05-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/casi-pharmaceuticals-to-host-conference-call-on-may-21-to-provide-business-and-clinical-updates 2025-05-19T23:17:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/casi-pharmaceuticals-to-host-conference-call-on-may-21-to-provide-business-and-clinical-updates 2025-05-19T23:17:06+00:00 hourly 0.9 https://trial.medpath.com/news/nextcell-pharma-strengthens-commercial-strategy-with-appointment-of-msc-therapy-expert-dr-eric-strati 2025-05-19T22:46:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nextcell-pharma-strengthens-commercial-strategy-with-appointment-of-msc-therapy-expert-dr-eric-strati 2025-05-19T22:46:26+00:00 hourly 0.9 https://trial.medpath.com/news/lexicon-s-sonata-hcm-phase-3-trial-design-unveiled-at-european-cardiology-congress 2025-05-19T22:45:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lexicon-s-sonata-hcm-phase-3-trial-design-unveiled-at-european-cardiology-congress 2025-05-19T22:45:33+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-considers-5-9-billion-biomanufacturing-facility-in-houston 2025-05-19T21:45:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-considers-5-9-billion-biomanufacturing-facility-in-houston 2025-05-19T21:45:54+00:00 hourly 0.9 https://trial.medpath.com/news/oligo-factory-expands-capabilities-with-new-low-scale-synthesis-platform-for-therapeutic-and-diagnostic-development 2025-05-19T21:44:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oligo-factory-expands-capabilities-with-new-low-scale-synthesis-platform-for-therapeutic-and-diagnostic-development 2025-05-19T21:44:18+00:00 hourly 0.9 https://trial.medpath.com/news/crispr-therapeutics-expands-into-sirna-therapies-with-95m-sirius-partnership-for-thromboembolic-disorders 2025-05-19T21:44:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crispr-therapeutics-expands-into-sirna-therapies-with-95m-sirius-partnership-for-thromboembolic-disorders 2025-05-19T21:44:16+00:00 hourly 0.9 https://trial.medpath.com/news/persist-ai-raises-12m-series-a-launches-cloud-lab-to-revolutionize-pharmaceutical-formulation-development 2025-05-19T21:17:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/persist-ai-raises-12m-series-a-launches-cloud-lab-to-revolutionize-pharmaceutical-formulation-development 2025-05-19T21:17:27+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-in-platelet-engineering-opens-new-avenues-for-targeted-drug-delivery 2025-05-19T20:37:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-in-platelet-engineering-opens-new-avenues-for-targeted-drug-delivery 2025-05-19T20:37:02+00:00 hourly 0.9 https://trial.medpath.com/news/federal-circuit-ruling-opens-new-patent-challenge-avenue-for-life-sciences-companies 2025-05-19T20:36:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-circuit-ruling-opens-new-patent-challenge-avenue-for-life-sciences-companies 2025-05-19T20:36:49+00:00 hourly 0.9 https://trial.medpath.com/news/taiwan-to-expand-national-health-insurance-coverage-for-cancer-immunotherapies-and-targeted-drugs 2025-05-19T20:36:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/taiwan-to-expand-national-health-insurance-coverage-for-cancer-immunotherapies-and-targeted-drugs 2025-05-19T20:36:03+00:00 hourly 0.9 https://trial.medpath.com/news/persist-ai-secures-12m-series-a-funding-to-revolutionize-pharmaceutical-formulation-development 2025-05-19T20:35:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/persist-ai-secures-12m-series-a-funding-to-revolutionize-pharmaceutical-formulation-development 2025-05-19T20:35:49+00:00 hourly 0.9 https://trial.medpath.com/news/sarepta-therapeutics-revises-2025-guidance-following-elevidys-safety-event-and-operational-challenges 2025-05-19T20:17:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sarepta-therapeutics-revises-2025-guidance-following-elevidys-safety-event-and-operational-challenges 2025-05-19T20:17:36+00:00 hourly 0.9 https://trial.medpath.com/news/kriya-therapeutics-presents-promising-preclinical-data-for-kriya-825-gene-therapy-in-geographic-atrophy 2025-05-19T20:17:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kriya-therapeutics-presents-promising-preclinical-data-for-kriya-825-gene-therapy-in-geographic-atrophy 2025-05-19T20:17:32+00:00 hourly 0.9 https://trial.medpath.com/news/ucb-and-domino-data-lab-partner-to-modernize-statistical-computing-for-accelerated-drug-development 2025-05-19T20:16:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ucb-and-domino-data-lab-partner-to-modernize-statistical-computing-for-accelerated-drug-development 2025-05-19T20:16:33+00:00 hourly 0.9 https://trial.medpath.com/news/nasa-awards-phase-ii-contract-to-yank-technologies-for-lunar-power-transmission-innovation 2025-05-19T20:16:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nasa-awards-phase-ii-contract-to-yank-technologies-for-lunar-power-transmission-innovation 2025-05-19T20:16:17+00:00 hourly 0.9 https://trial.medpath.com/news/arineta-s-spotlight-duo-ct-scanner-receives-fda-clearance-for-lung-cancer-screening 2025-05-19T20:16:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arineta-s-spotlight-duo-ct-scanner-receives-fda-clearance-for-lung-cancer-screening 2025-05-19T20:16:01+00:00 hourly 0.9 https://trial.medpath.com/news/fda-s-approval-of-mrd-as-end-point-transforms-multiple-myeloma-research-and-treatment 2025-05-19T20:15:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-s-approval-of-mrd-as-end-point-transforms-multiple-myeloma-research-and-treatment 2025-05-19T20:15:02+00:00 hourly 0.9 https://trial.medpath.com/news/k2-medical-research-launches-new-clinical-trials-program-in-rhode-island-focusing-on-alzheimer-s-disease 2025-05-19T20:14:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/k2-medical-research-launches-new-clinical-trials-program-in-rhode-island-focusing-on-alzheimer-s-disease 2025-05-19T20:14:21+00:00 hourly 0.9 https://trial.medpath.com/news/ionis-reports-positive-phase-3-results-for-olezarsen-in-hypertriglyceridemia 2025-05-19T19:41:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ionis-reports-positive-phase-3-results-for-olezarsen-in-hypertriglyceridemia 2025-05-19T19:41:59+00:00 hourly 0.9 https://trial.medpath.com/news/ensifentrine-shows-promise-as-novel-monotherapy-and-add-on-treatment-for-copd 2025-05-19T19:41:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ensifentrine-shows-promise-as-novel-monotherapy-and-add-on-treatment-for-copd 2025-05-19T19:41:52+00:00 hourly 0.9 https://trial.medpath.com/news/batura-trial-airsupra-reduces-severe-asthma-exacerbation-risk-by-47-compared-to-albuterol-alone 2025-05-19T19:40:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/batura-trial-airsupra-reduces-severe-asthma-exacerbation-risk-by-47-compared-to-albuterol-alone 2025-05-19T19:40:17+00:00 hourly 0.9 https://trial.medpath.com/news/fda-expands-jivi-approval-for-hemophilia-a-treatment-in-children-ages-7-12 2025-05-19T18:45:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-expands-jivi-approval-for-hemophilia-a-treatment-in-children-ages-7-12 2025-05-19T18:45:28+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-repair-biotechnologies-mrna-therapy-for-rare-cholesterol-disorder 2025-05-19T18:15:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-designation-to-repair-biotechnologies-mrna-therapy-for-rare-cholesterol-disorder 2025-05-19T18:15:30+00:00 hourly 0.9 https://trial.medpath.com/news/gradient-s-pulmonary-artery-denervation-system-receives-fda-breakthrough-designation-for-pulmonary-hypertension 2025-05-19T17:43:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gradient-s-pulmonary-artery-denervation-system-receives-fda-breakthrough-designation-for-pulmonary-hypertension 2025-05-19T17:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/cellcentric-secures-120-million-series-c-funding-to-advance-oral-multiple-myeloma-treatment 2025-05-19T16:47:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellcentric-secures-120-million-series-c-funding-to-advance-oral-multiple-myeloma-treatment 2025-05-19T16:47:37+00:00 hourly 0.9 https://trial.medpath.com/news/prime-medicine-restructures-ceo-replaced-25-staff-cut-and-lead-program-halted 2025-05-19T16:47:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prime-medicine-restructures-ceo-replaced-25-staff-cut-and-lead-program-halted 2025-05-19T16:47:33+00:00 hourly 0.9 https://trial.medpath.com/news/gt-biopharma-advances-gtb-3650-phase-1-trial-to-second-cohort-following-promising-immune-activation-signals 2025-05-19T16:46:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gt-biopharma-advances-gtb-3650-phase-1-trial-to-second-cohort-following-promising-immune-activation-signals 2025-05-19T16:46:45+00:00 hourly 0.9 https://trial.medpath.com/news/reunion-neuroscience-completes-patient-dosing-in-phase-2-trial-of-novel-psychedelic-for-postpartum-depression 2025-05-19T16:46:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/reunion-neuroscience-completes-patient-dosing-in-phase-2-trial-of-novel-psychedelic-for-postpartum-depression 2025-05-19T16:46:43+00:00 hourly 0.9 https://trial.medpath.com/news/respira-therapeutics-to-present-phase-2b-results-of-rt234-inhalation-therapy-for-pah-at-ats-2025 2025-05-19T16:46:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/respira-therapeutics-to-present-phase-2b-results-of-rt234-inhalation-therapy-for-pah-at-ats-2025 2025-05-19T16:46:39+00:00 hourly 0.9 https://trial.medpath.com/news/eascra-biotech-secures-100000-massventures-grant-for-novel-nanoparticle-drug-delivery-platform 2025-05-19T16:44:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eascra-biotech-secures-100000-massventures-grant-for-novel-nanoparticle-drug-delivery-platform 2025-05-19T16:44:35+00:00 hourly 0.9 https://trial.medpath.com/news/juvena-therapeutics-initiates-first-in-human-trial-of-juv-161-for-muscle-regeneration-in-myotonic-dystrophy 2025-05-19T16:22:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/juvena-therapeutics-initiates-first-in-human-trial-of-juv-161-for-muscle-regeneration-in-myotonic-dystrophy 2025-05-19T16:22:07+00:00 hourly 0.9 https://trial.medpath.com/news/recludix-s-stat6-inhibitor-shows-promising-efficacy-in-preclinical-asthma-model-matching-biologic-treatments 2025-05-19T16:22:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/recludix-s-stat6-inhibitor-shows-promising-efficacy-in-preclinical-asthma-model-matching-biologic-treatments 2025-05-19T16:22:05+00:00 hourly 0.9 https://trial.medpath.com/news/cordis-launches-10000-patient-global-registry-for-selution-slr-drug-eluting-balloon 2025-05-19T16:21:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cordis-launches-10000-patient-global-registry-for-selution-slr-drug-eluting-balloon 2025-05-19T16:21:52+00:00 hourly 0.9 https://trial.medpath.com/news/appili-therapeutics-terminates-1m-acquisition-deal-with-aditxt-secures-loan-extensions 2025-05-19T16:21:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/appili-therapeutics-terminates-1m-acquisition-deal-with-aditxt-secures-loan-extensions 2025-05-19T16:21:31+00:00 hourly 0.9 https://trial.medpath.com/news/rani-therapeutics-and-chugai-pharmaceutical-partner-to-advance-oral-antibody-delivery-technology 2025-05-19T16:20:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rani-therapeutics-and-chugai-pharmaceutical-partner-to-advance-oral-antibody-delivery-technology 2025-05-19T16:20:13+00:00 hourly 0.9 https://trial.medpath.com/news/fujifilm-validates-novel-peptide-oligonucleotide-conjugates-for-targeted-cancer-cell-delivery 2025-05-19T16:20:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fujifilm-validates-novel-peptide-oligonucleotide-conjugates-for-targeted-cancer-cell-delivery 2025-05-19T16:20:11+00:00 hourly 0.9 https://trial.medpath.com/news/prime-medicine-reports-breakthrough-clinical-data-for-first-prime-editing-therapy-in-chronic-granulomatous-disease 2025-05-19T16:17:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prime-medicine-reports-breakthrough-clinical-data-for-first-prime-editing-therapy-in-chronic-granulomatous-disease 2025-05-19T16:17:57+00:00 hourly 0.9 https://trial.medpath.com/news/ainos-reports-promising-interim-results-for-veldona-in-feline-chronic-gingivostomatitis-treatment 2025-05-19T16:17:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ainos-reports-promising-interim-results-for-veldona-in-feline-chronic-gingivostomatitis-treatment 2025-05-19T16:17:55+00:00 hourly 0.9 https://trial.medpath.com/news/scientists-develop-successful-blood-vessel-implants-in-rats 2025-05-19T16:17:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scientists-develop-successful-blood-vessel-implants-in-rats 2025-05-19T16:17:15+00:00 hourly 0.9 https://trial.medpath.com/news/ruxoprubart-shows-promising-phase-ii-results-as-novel-monotherapy-for-paroxysmal-nocturnal-hemoglobinuria 2025-05-19T16:17:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ruxoprubart-shows-promising-phase-ii-results-as-novel-monotherapy-for-paroxysmal-nocturnal-hemoglobinuria 2025-05-19T16:17:13+00:00 hourly 0.9 https://trial.medpath.com/news/global-gvhd-clinical-trials-review-reveals-key-trends-and-strategic-opportunities-for-2025 2025-05-19T16:16:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-gvhd-clinical-trials-review-reveals-key-trends-and-strategic-opportunities-for-2025 2025-05-19T16:16:32+00:00 hourly 0.9 https://trial.medpath.com/news/gustave-roussy-launches-umbrella-trial-using-blood-based-tumor-dna-to-revolutionize-cancer-follow-up-care 2025-05-19T16:16:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gustave-roussy-launches-umbrella-trial-using-blood-based-tumor-dna-to-revolutionize-cancer-follow-up-care 2025-05-19T16:16:20+00:00 hourly 0.9 https://trial.medpath.com/news/siscapa-and-biognosys-partner-to-advance-protein-biomarker-analysis-for-clinical-trials 2025-05-19T16:16:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/siscapa-and-biognosys-partner-to-advance-protein-biomarker-analysis-for-clinical-trials 2025-05-19T16:16:18+00:00 hourly 0.9 https://trial.medpath.com/news/robust-pipeline-of-50-therapies-reshaping-moderate-to-severe-atopic-dermatitis-treatment-landscape 2025-05-19T16:16:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/robust-pipeline-of-50-therapies-reshaping-moderate-to-severe-atopic-dermatitis-treatment-landscape 2025-05-19T16:16:16+00:00 hourly 0.9 https://trial.medpath.com/news/rejuvenate-biomed-initiates-phase-ii-trial-of-rjx-01-for-copd-related-muscle-weakness 2025-05-19T16:16:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rejuvenate-biomed-initiates-phase-ii-trial-of-rjx-01-for-copd-related-muscle-weakness 2025-05-19T16:16:12+00:00 hourly 0.9 https://trial.medpath.com/news/surgical-robotics-advance-endoquest-and-virtuoso-begin-first-human-trials-for-minimally-invasive-procedures 2025-05-19T16:16:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/surgical-robotics-advance-endoquest-and-virtuoso-begin-first-human-trials-for-minimally-invasive-procedures 2025-05-19T16:16:10+00:00 hourly 0.9 https://trial.medpath.com/news/olaris-secures-strategic-investment-from-bruker-to-advance-metabolomics-diagnostic-platform 2025-05-19T16:15:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/olaris-secures-strategic-investment-from-bruker-to-advance-metabolomics-diagnostic-platform 2025-05-19T16:15:27+00:00 hourly 0.9 https://trial.medpath.com/news/stanford-researchers-develop-synthetic-molecule-that-targets-and-eliminates-breast-and-pancreatic-cancers 2025-05-19T16:15:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stanford-researchers-develop-synthetic-molecule-that-targets-and-eliminates-breast-and-pancreatic-cancers 2025-05-19T16:15:18+00:00 hourly 0.9 https://trial.medpath.com/news/teva-pharmaceutical-launches-2-billion-senior-notes-offering-to-restructure-debt 2025-05-19T15:11:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/teva-pharmaceutical-launches-2-billion-senior-notes-offering-to-restructure-debt 2025-05-19T15:11:37+00:00 hourly 0.9 https://trial.medpath.com/news/acg-unveils-patented-personalized-capsule-machine-for-custom-supplement-formulation 2025-05-19T14:40:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acg-unveils-patented-personalized-capsule-machine-for-custom-supplement-formulation 2025-05-19T14:40:05+00:00 hourly 0.9 https://trial.medpath.com/news/cytomx-doses-first-patient-in-combination-trial-of-cx-801-with-keytruda-for-metastatic-melanoma 2025-05-19T12:47:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cytomx-doses-first-patient-in-combination-trial-of-cx-801-with-keytruda-for-metastatic-melanoma 2025-05-19T12:47:53+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-and-karolinska-institutet-celebrate-decade-of-collaboration-advancing-medical-innovations 2025-05-19T12:47:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-and-karolinska-institutet-celebrate-decade-of-collaboration-advancing-medical-innovations 2025-05-19T12:47:52+00:00 hourly 0.9 https://trial.medpath.com/news/ab-science-secures-chinese-patent-for-masitinib-in-covid-19-treatment-until-2041 2025-05-19T12:47:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ab-science-secures-chinese-patent-for-masitinib-in-covid-19-treatment-until-2041 2025-05-19T12:47:18+00:00 hourly 0.9 https://trial.medpath.com/news/astellas-to-present-new-long-term-survival-data-for-cancer-therapies-at-asco-2025 2025-05-19T12:47:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astellas-to-present-new-long-term-survival-data-for-cancer-therapies-at-asco-2025 2025-05-19T12:47:04+00:00 hourly 0.9 https://trial.medpath.com/news/evolving-treatment-landscape-for-metastatic-hormone-sensitive-prostate-cancer-beyond-adt-monotherapy 2025-05-19T12:47:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evolving-treatment-landscape-for-metastatic-hormone-sensitive-prostate-cancer-beyond-adt-monotherapy 2025-05-19T12:47:03+00:00 hourly 0.9 https://trial.medpath.com/news/ema-designates-allopurinol-as-first-orphan-drug-for-marfan-syndrome 2025-05-19T12:45:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-designates-allopurinol-as-first-orphan-drug-for-marfan-syndrome 2025-05-19T12:45:26+00:00 hourly 0.9 https://trial.medpath.com/news/scientific-breakthrough-reveals-how-alpha1h-targets-bladder-cancer-cells 2025-05-19T12:44:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scientific-breakthrough-reveals-how-alpha1h-targets-bladder-cancer-cells 2025-05-19T12:44:41+00:00 hourly 0.9 https://trial.medpath.com/news/protagenic-and-phytanix-merge-to-form-neuroactive-biopharmaceutical-company-with-obesity-drug-in-development 2025-05-19T12:43:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/protagenic-and-phytanix-merge-to-form-neuroactive-biopharmaceutical-company-with-obesity-drug-in-development 2025-05-19T12:43:35+00:00 hourly 0.9 https://trial.medpath.com/news/dextech-medical-secures-european-patent-for-osteodex-gmp-manufacturing-until-2045 2025-05-19T12:12:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dextech-medical-secures-european-patent-for-osteodex-gmp-manufacturing-until-2045 2025-05-19T12:12:43+00:00 hourly 0.9 https://trial.medpath.com/news/taiwan-approves-chugai-s-piasky-as-first-subcutaneous-treatment-for-paroxysmal-nocturnal-hemoglobinuria 2025-05-19T12:12:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/taiwan-approves-chugai-s-piasky-as-first-subcutaneous-treatment-for-paroxysmal-nocturnal-hemoglobinuria 2025-05-19T12:12:41+00:00 hourly 0.9 https://trial.medpath.com/news/massalia-therapeutics-launches-with-seed-funding-to-target-fibrosis-neoplasm-neovascularization-interface 2025-05-19T12:11:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/massalia-therapeutics-launches-with-seed-funding-to-target-fibrosis-neoplasm-neovascularization-interface 2025-05-19T12:11:43+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-to-acquire-23andme-for-256-million-expanding-genetics-driven-drug-discovery-capabilities 2025-05-19T12:11:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regeneron-to-acquire-23andme-for-256-million-expanding-genetics-driven-drug-discovery-capabilities 2025-05-19T12:11:36+00:00 hourly 0.9 https://trial.medpath.com/news/akantior-r-receives-uk-marketing-authorization-as-first-approved-treatment-for-acanthamoeba-keratitis 2025-05-19T12:11:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/akantior-r-receives-uk-marketing-authorization-as-first-approved-treatment-for-acanthamoeba-keratitis 2025-05-19T12:11:31+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-18-new-personalized-medicines-in-2024-marking-significant-shift-in-treatment-paradigm 2025-05-19T12:11:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-18-new-personalized-medicines-in-2024-marking-significant-shift-in-treatment-paradigm 2025-05-19T12:11:25+00:00 hourly 0.9 https://trial.medpath.com/news/vesalius-real-study-reveals-critical-gaps-in-cardiovascular-care-despite-available-treatments 2025-05-19T12:11:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vesalius-real-study-reveals-critical-gaps-in-cardiovascular-care-despite-available-treatments 2025-05-19T12:11:15+00:00 hourly 0.9 https://trial.medpath.com/news/merck-and-daiichi-sankyo-launch-phase-3-trial-of-novel-b7-h3-targeted-adc-for-advanced-esophageal-cancer 2025-05-19T12:11:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-and-daiichi-sankyo-launch-phase-3-trial-of-novel-b7-h3-targeted-adc-for-advanced-esophageal-cancer 2025-05-19T12:11:11+00:00 hourly 0.9 https://trial.medpath.com/news/taiwan-administers-first-alzheimer-s-drug-targeting-amyloid-plaques 2025-05-19T10:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/taiwan-administers-first-alzheimer-s-drug-targeting-amyloid-plaques 2025-05-19T10:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cipla-receives-vai-status-from-usfda-for-two-manufacturing-facilities 2025-05-19T09:15:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cipla-receives-vai-status-from-usfda-for-two-manufacturing-facilities 2025-05-19T09:15:41+00:00 hourly 0.9 https://trial.medpath.com/news/new-mainland-chinese-cancer-drug-shows-promising-results-in-phase-1-trial 2025-05-19T08:37:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-mainland-chinese-cancer-drug-shows-promising-results-in-phase-1-trial 2025-05-19T08:37:23+00:00 hourly 0.9 https://trial.medpath.com/news/fda-rejects-immunitybio-s-expanded-anktiva-application-while-lifting-hold-on-atara-s-ebvallo-trials 2025-05-19T08:37:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-rejects-immunitybio-s-expanded-anktiva-application-while-lifting-hold-on-atara-s-ebvallo-trials 2025-05-19T08:37:22+00:00 hourly 0.9 https://trial.medpath.com/news/eur13-6m-eu-funded-predi-lynch-project-aims-to-transform-cancer-screening-for-lynch-syndrome-patients 2025-05-19T08:37:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eur13-6m-eu-funded-predi-lynch-project-aims-to-transform-cancer-screening-for-lynch-syndrome-patients 2025-05-19T08:37:18+00:00 hourly 0.9 https://trial.medpath.com/news/azvudine-shows-comparable-effectiveness-to-nirmatrelvir-ritonavir-for-covid-19-patients-with-chronic-liver-disease 2025-05-19T08:37:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/azvudine-shows-comparable-effectiveness-to-nirmatrelvir-ritonavir-for-covid-19-patients-with-chronic-liver-disease 2025-05-19T08:37:07+00:00 hourly 0.9 https://trial.medpath.com/news/immupharma-advances-p140-autoimmune-program-with-novel-non-immunosuppressive-mechanism 2025-05-19T08:36:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immupharma-advances-p140-autoimmune-program-with-novel-non-immunosuppressive-mechanism 2025-05-19T08:36:16+00:00 hourly 0.9 https://trial.medpath.com/news/new-teletrial-model-brings-hope-to-severe-eczema-patients-in-regional-areas 2025-05-19T08:05:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-teletrial-model-brings-hope-to-severe-eczema-patients-in-regional-areas 2025-05-19T08:05:54+00:00 hourly 0.9 https://trial.medpath.com/news/sleep-disturbances-in-icu-patients-new-research-reveals-impact-on-recovery-and-outcomes 2025-05-19T04:35:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sleep-disturbances-in-icu-patients-new-research-reveals-impact-on-recovery-and-outcomes 2025-05-19T04:35:25+00:00 hourly 0.9 https://trial.medpath.com/news/india-s-corbevax-covid-19-vaccine-upgraded-from-emergency-use-to-full-drug-approval-for-ages-5-and-above 2025-05-19T04:11:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-s-corbevax-covid-19-vaccine-upgraded-from-emergency-use-to-full-drug-approval-for-ages-5-and-above 2025-05-19T04:11:56+00:00 hourly 0.9 https://trial.medpath.com/news/medicare-low-income-drug-subsidy-loss-linked-to-higher-mortality-rates 2025-05-19T04:09:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medicare-low-income-drug-subsidy-loss-linked-to-higher-mortality-rates 2025-05-19T04:09:33+00:00 hourly 0.9 https://trial.medpath.com/news/weight-gain-combined-with-delayed-motherhood-nearly-triples-breast-cancer-risk-study-finds 2025-05-19T04:07:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/weight-gain-combined-with-delayed-motherhood-nearly-triples-breast-cancer-risk-study-finds 2025-05-19T04:07:23+00:00 hourly 0.9 https://trial.medpath.com/news/wegovy-prescriptions-for-us-teens-surge-50-as-weight-loss-surgery-also-rises-despite-glp-1-drug-availability 2025-05-19T04:07:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wegovy-prescriptions-for-us-teens-surge-50-as-weight-loss-surgery-also-rises-despite-glp-1-drug-availability 2025-05-19T04:07:22+00:00 hourly 0.9 https://trial.medpath.com/news/new-lung-allocation-system-reduces-waitlist-deaths-by-75-since-2023-implementation 2025-05-19T03:05:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-lung-allocation-system-reduces-waitlist-deaths-by-75-since-2023-implementation 2025-05-19T03:05:30+00:00 hourly 0.9 https://trial.medpath.com/news/dupilumab-reduces-asthma-exacerbations-in-children-regardless-of-disease-duration 2025-05-19T02:36:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dupilumab-reduces-asthma-exacerbations-in-children-regardless-of-disease-duration 2025-05-19T02:36:27+00:00 hourly 0.9 https://trial.medpath.com/news/former-president-biden-diagnosed-with-metastatic-prostate-cancer 2025-05-19T02:36:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/former-president-biden-diagnosed-with-metastatic-prostate-cancer 2025-05-19T02:36:12+00:00 hourly 0.9 https://trial.medpath.com/news/post-marketing-safety-analysis-of-voclosporin-reveals-new-adverse-event-patterns-in-lupus-nephritis-treatment 2025-05-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/post-marketing-safety-analysis-of-voclosporin-reveals-new-adverse-event-patterns-in-lupus-nephritis-treatment 2025-05-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-brainstorm-cell-therapeutics-phase-3b-trial-of-nurown-for-als-treatment 2025-05-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-brainstorm-cell-therapeutics-phase-3b-trial-of-nurown-for-als-treatment 2025-05-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/uc-davis-scientists-develop-non-hallucinogenic-lsd-derivative-that-shows-promise-for-schizophrenia-treatment 2025-05-18T22:36:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uc-davis-scientists-develop-non-hallucinogenic-lsd-derivative-that-shows-promise-for-schizophrenia-treatment 2025-05-18T22:36:46+00:00 hourly 0.9 https://trial.medpath.com/news/interpace-biosciences-secures-us-patent-for-microrna-technology-in-thyroid-cancer-diagnosis 2025-05-18T20:37:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/interpace-biosciences-secures-us-patent-for-microrna-technology-in-thyroid-cancer-diagnosis 2025-05-18T20:37:34+00:00 hourly 0.9 https://trial.medpath.com/news/rhone-x-trial-faricimab-shows-sustained-4-year-benefits-with-reduced-injection-burden-in-dme-patients 2025-05-18T20:35:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rhone-x-trial-faricimab-shows-sustained-4-year-benefits-with-reduced-injection-burden-in-dme-patients 2025-05-18T20:35:23+00:00 hourly 0.9 https://trial.medpath.com/news/imvaria-presents-real-world-data-on-fda-authorized-ai-diagnostic-service-for-pulmonary-fibrosis-at-ats-2025 2025-05-18T16:35:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imvaria-presents-real-world-data-on-fda-authorized-ai-diagnostic-service-for-pulmonary-fibrosis-at-ats-2025 2025-05-18T16:35:53+00:00 hourly 0.9 https://trial.medpath.com/news/uk-government-announces-10-year-r-d-funding-initiative-to-boost-pharmaceutical-research 2025-05-18T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-government-announces-10-year-r-d-funding-initiative-to-boost-pharmaceutical-research 2025-05-18T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/scilex-publishes-gloperba-dosing-guidelines-for-gout-patients-with-kidney-impairment 2025-05-18T14:35:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scilex-publishes-gloperba-dosing-guidelines-for-gout-patients-with-kidney-impairment 2025-05-18T14:35:45+00:00 hourly 0.9 https://trial.medpath.com/news/fecal-microbiota-therapy-shows-95-success-rate-in-preventing-recurrent-c-difficile-infection 2025-05-18T13:41:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fecal-microbiota-therapy-shows-95-success-rate-in-preventing-recurrent-c-difficile-infection 2025-05-18T13:41:29+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-novavax-covid-19-vaccine-with-restricted-use-for-high-risk-groups 2025-05-18T09:06:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-novavax-covid-19-vaccine-with-restricted-use-for-high-risk-groups 2025-05-18T09:06:33+00:00 hourly 0.9 https://trial.medpath.com/news/cdsco-approves-astrazeneca-s-protocol-amendments-for-durvalumab-tremelimumab-combination-in-advanced-liver-cancer 2025-05-18T04:37:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdsco-approves-astrazeneca-s-protocol-amendments-for-durvalumab-tremelimumab-combination-in-advanced-liver-cancer 2025-05-18T04:37:18+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-receives-cdsco-approval-for-phase-3-trial-of-her2-targeting-adc-disitamab-vedotin 2025-05-18T04:37:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-receives-cdsco-approval-for-phase-3-trial-of-her2-targeting-adc-disitamab-vedotin 2025-05-18T04:37:12+00:00 hourly 0.9 https://trial.medpath.com/news/onco-dermatology-emerges-as-critical-component-of-multidisciplinary-cancer-care 2025-05-18T03:06:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/onco-dermatology-emerges-as-critical-component-of-multidisciplinary-cancer-care 2025-05-18T03:06:24+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-sparsentan-snda-for-full-approval-in-focal-segmental-glomerulosclerosis 2025-05-18T03:06:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-accepts-sparsentan-snda-for-full-approval-in-focal-segmental-glomerulosclerosis 2025-05-18T03:06:21+00:00 hourly 0.9 https://trial.medpath.com/news/stem-cell-transplant-maintains-cost-effective-role-despite-novel-multiple-myeloma-therapies 2025-05-18T02:35:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stem-cell-transplant-maintains-cost-effective-role-despite-novel-multiple-myeloma-therapies 2025-05-18T02:35:21+00:00 hourly 0.9 https://trial.medpath.com/news/usfda-issues-form-483-with-two-observations-for-dr-reddy-s-new-york-api-facility 2025-05-18T00:41:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/usfda-issues-form-483-with-two-observations-for-dr-reddy-s-new-york-api-facility 2025-05-18T00:41:29+00:00 hourly 0.9 https://trial.medpath.com/news/silo-pharma-secures-2-million-in-public-offering-to-advance-cns-and-pain-therapeutics 2025-05-18T00:40:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/silo-pharma-secures-2-million-in-public-offering-to-advance-cns-and-pain-therapeutics 2025-05-18T00:40:51+00:00 hourly 0.9 https://trial.medpath.com/news/long-acting-antiviral-cd388-shows-76-efficacy-against-flu-in-phase-3-trial 2025-05-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/long-acting-antiviral-cd388-shows-76-efficacy-against-flu-in-phase-3-trial 2025-05-18T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sylentis-reports-positive-phase-iia-results-for-syl1801-eye-drops-in-age-related-macular-degeneration 2025-05-17T20:12:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sylentis-reports-positive-phase-iia-results-for-syl1801-eye-drops-in-age-related-macular-degeneration 2025-05-17T20:12:21+00:00 hourly 0.9 https://trial.medpath.com/news/alzheimer-s-drug-discovery-foundation-partners-with-siemens-healthineers-to-license-speechdx-dataset-for-speech-based-biomarker-development 2025-05-17T18:11:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alzheimer-s-drug-discovery-foundation-partners-with-siemens-healthineers-to-license-speechdx-dataset-for-speech-based-biomarker-development 2025-05-17T18:11:58+00:00 hourly 0.9 https://trial.medpath.com/news/panjab-university-patents-breakthrough-green-nanomicelle-platform-for-pharmaceutical-and-skincare-applications 2025-05-17T16:41:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/panjab-university-patents-breakthrough-green-nanomicelle-platform-for-pharmaceutical-and-skincare-applications 2025-05-17T16:41:52+00:00 hourly 0.9 https://trial.medpath.com/news/brain-cancer-canada-funds-68000-for-innovative-dipg-vaccine-clinical-trial 2025-05-17T16:41:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brain-cancer-canada-funds-68000-for-innovative-dipg-vaccine-clinical-trial 2025-05-17T16:41:35+00:00 hourly 0.9 https://trial.medpath.com/news/kakao-healthcare-expands-ai-powered-glucose-monitoring-app-to-japanese-market 2025-05-17T16:41:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kakao-healthcare-expands-ai-powered-glucose-monitoring-app-to-japanese-market 2025-05-17T16:41:30+00:00 hourly 0.9 https://trial.medpath.com/news/bgg-expands-world-s-largest-astaxanthin-facility-in-china-doubles-r-d-capacity 2025-05-17T16:41:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bgg-expands-world-s-largest-astaxanthin-facility-in-china-doubles-r-d-capacity 2025-05-17T16:41:14+00:00 hourly 0.9 https://trial.medpath.com/news/trump-s-most-favored-nation-drug-pricing-policy-threatens-german-pharma-industry 2025-05-17T16:41:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-s-most-favored-nation-drug-pricing-policy-threatens-german-pharma-industry 2025-05-17T16:41:11+00:00 hourly 0.9 https://trial.medpath.com/news/black-women-face-disproportionate-advanced-stage-cancer-diagnoses-amid-growing-healthcare-access-barriers 2025-05-17T15:35:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/black-women-face-disproportionate-advanced-stage-cancer-diagnoses-amid-growing-healthcare-access-barriers 2025-05-17T15:35:16+00:00 hourly 0.9 https://trial.medpath.com/news/tessera-therapeutics-reports-breakthrough-gene-editing-results-for-multiple-genetic-diseases 2025-05-17T12:35:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tessera-therapeutics-reports-breakthrough-gene-editing-results-for-multiple-genetic-diseases 2025-05-17T12:35:55+00:00 hourly 0.9 https://trial.medpath.com/news/pharmaceutical-grade-cannabidiol-shows-promising-cardiac-safety-profile-in-high-risk-patients 2025-05-17T12:35:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmaceutical-grade-cannabidiol-shows-promising-cardiac-safety-profile-in-high-risk-patients 2025-05-17T12:35:49+00:00 hourly 0.9 https://trial.medpath.com/news/thermo-fisher-scientific-launches-cell-and-gene-therapy-vision-centre-in-south-korea-to-accelerate-advanced-therapeutic-development 2025-05-17T12:35:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thermo-fisher-scientific-launches-cell-and-gene-therapy-vision-centre-in-south-korea-to-accelerate-advanced-therapeutic-development 2025-05-17T12:35:32+00:00 hourly 0.9 https://trial.medpath.com/news/el1ssar-trial-confirms-efficacy-of-atezolizumab-plus-nab-paclitaxel-in-pd-l1-positive-advanced-tnbc 2025-05-17T12:35:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/el1ssar-trial-confirms-efficacy-of-atezolizumab-plus-nab-paclitaxel-in-pd-l1-positive-advanced-tnbc 2025-05-17T12:35:19+00:00 hourly 0.9 https://trial.medpath.com/news/fractyl-health-s-novel-smart-glp-1-gene-therapy-shows-promise-for-diabetes-and-obesity-treatment 2025-05-17T12:09:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fractyl-health-s-novel-smart-glp-1-gene-therapy-shows-promise-for-diabetes-and-obesity-treatment 2025-05-17T12:09:48+00:00 hourly 0.9 https://trial.medpath.com/news/eisai-s-remitoro-clears-post-marketing-surveillance-requirements-for-t-cell-lymphoma-treatment-in-japan 2025-05-17T12:09:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eisai-s-remitoro-clears-post-marketing-surveillance-requirements-for-t-cell-lymphoma-treatment-in-japan 2025-05-17T12:09:38+00:00 hourly 0.9 https://trial.medpath.com/news/ai-in-oncology-transforming-community-practice-from-patient-care-to-revenue-cycles 2025-05-17T10:36:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-in-oncology-transforming-community-practice-from-patient-care-to-revenue-cycles 2025-05-17T10:36:04+00:00 hourly 0.9 https://trial.medpath.com/news/first-biologic-drug-for-pulmonary-sarcoidosis-in-50-years-administered-at-oxford-hospital 2025-05-17T08:36:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-biologic-drug-for-pulmonary-sarcoidosis-in-50-years-administered-at-oxford-hospital 2025-05-17T08:36:15+00:00 hourly 0.9 https://trial.medpath.com/news/fezolinetant-shows-promising-body-composition-benefits-for-menopausal-women-in-phase-3-trials 2025-05-17T08:35:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fezolinetant-shows-promising-body-composition-benefits-for-menopausal-women-in-phase-3-trials 2025-05-17T08:35:51+00:00 hourly 0.9 https://trial.medpath.com/news/cardioplexoltm-demonstrates-safety-and-efficacy-in-phase-3-trial-for-cardiac-surgery 2025-05-17T06:41:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cardioplexoltm-demonstrates-safety-and-efficacy-in-phase-3-trial-for-cardiac-surgery 2025-05-17T06:41:53+00:00 hourly 0.9 https://trial.medpath.com/news/fda-advisory-committee-rejects-urogen-s-bladder-cancer-therapy-ugn-102 2025-05-17T06:41:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-advisory-committee-rejects-urogen-s-bladder-cancer-therapy-ugn-102 2025-05-17T06:41:42+00:00 hourly 0.9 https://trial.medpath.com/news/landmark-va-study-reveals-genomic-differences-in-metastatic-prostate-cancer-across-racial-groups 2025-05-17T04:39:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/landmark-va-study-reveals-genomic-differences-in-metastatic-prostate-cancer-across-racial-groups 2025-05-17T04:39:38+00:00 hourly 0.9 https://trial.medpath.com/news/sp-102-shows-clinically-meaningful-results-for-sciatica-treatment-in-clear-trial-analysis 2025-05-17T04:39:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sp-102-shows-clinically-meaningful-results-for-sciatica-treatment-in-clear-trial-analysis 2025-05-17T04:39:26+00:00 hourly 0.9 https://trial.medpath.com/news/china-approves-first-domestically-developed-enzyme-replacement-therapy-for-gaucher-disease 2025-05-17T04:39:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-approves-first-domestically-developed-enzyme-replacement-therapy-for-gaucher-disease 2025-05-17T04:39:24+00:00 hourly 0.9 https://trial.medpath.com/news/biacure-secures-2-6m-nih-grant-to-develop-novel-high-frequency-energy-treatment-for-onychomycosis 2025-05-17T04:12:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biacure-secures-2-6m-nih-grant-to-develop-novel-high-frequency-energy-treatment-for-onychomycosis 2025-05-17T04:12:15+00:00 hourly 0.9 https://trial.medpath.com/news/resistance-mechanisms-drive-personalized-treatment-selection-after-osimertinib-failure-in-egfr-mutant-nsclc 2025-05-17T03:12:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/resistance-mechanisms-drive-personalized-treatment-selection-after-osimertinib-failure-in-egfr-mutant-nsclc 2025-05-17T03:12:53+00:00 hourly 0.9 https://trial.medpath.com/news/attr-cm-treatment-landscape-expands-with-three-fda-approved-disease-modifying-therapies 2025-05-17T02:40:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/attr-cm-treatment-landscape-expands-with-three-fda-approved-disease-modifying-therapies 2025-05-17T02:40:59+00:00 hourly 0.9 https://trial.medpath.com/news/abelzeta-s-c-car168-shows-promising-results-in-treating-refractory-lupus-nephritis-and-multiple-sclerosis 2025-05-17T02:40:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abelzeta-s-c-car168-shows-promising-results-in-treating-refractory-lupus-nephritis-and-multiple-sclerosis 2025-05-17T02:40:32+00:00 hourly 0.9 https://trial.medpath.com/news/alvotech-expands-european-presence-with-successful-nasdaq-stockholm-listing 2025-05-17T02:12:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alvotech-expands-european-presence-with-successful-nasdaq-stockholm-listing 2025-05-17T02:12:27+00:00 hourly 0.9 https://trial.medpath.com/news/endo-expands-adrenalin-r-ready-to-use-premixed-bag-line-with-new-8-mg-250-ml-concentration-for-septic-shock 2025-05-17T01:39:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/endo-expands-adrenalin-r-ready-to-use-premixed-bag-line-with-new-8-mg-250-ml-concentration-for-septic-shock 2025-05-17T01:39:40+00:00 hourly 0.9 https://trial.medpath.com/news/fda-deputy-commissioner-signals-potential-overhaul-of-pdufa-reauthorization-structure 2025-05-17T00:42:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-deputy-commissioner-signals-potential-overhaul-of-pdufa-reauthorization-structure 2025-05-17T00:42:31+00:00 hourly 0.9 https://trial.medpath.com/news/remedy-plan-therapeutics-secures-18-million-to-advance-novel-nampt-inhibitor-for-aml-and-mds-treatment 2025-05-17T00:42:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/remedy-plan-therapeutics-secures-18-million-to-advance-novel-nampt-inhibitor-for-aml-and-mds-treatment 2025-05-17T00:42:01+00:00 hourly 0.9 https://trial.medpath.com/news/federal-court-backs-hhs-in-340b-drug-pricing-dispute-with-major-pharmaceutical-companies 2025-05-17T00:41:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-court-backs-hhs-in-340b-drug-pricing-dispute-with-major-pharmaceutical-companies 2025-05-17T00:41:56+00:00 hourly 0.9 https://trial.medpath.com/news/amneal-pharmaceuticals-reports-strong-q1-2025-results-with-5-revenue-growth-and-margin-expansion 2025-05-17T00:41:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amneal-pharmaceuticals-reports-strong-q1-2025-results-with-5-revenue-growth-and-margin-expansion 2025-05-17T00:41:47+00:00 hourly 0.9 https://trial.medpath.com/news/izotropic-secures-fda-regulatory-alignment-for-izoview-breast-ct-system-advances-toward-pivotal-clinical-trial 2025-05-16T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/izotropic-secures-fda-regulatory-alignment-for-izoview-breast-ct-system-advances-toward-pivotal-clinical-trial 2025-05-16T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/gan-lee-pharmaceuticals-partners-with-brazil-to-localize-insulin-production-in-landmark-agreement 2025-05-16T22:43:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gan-lee-pharmaceuticals-partners-with-brazil-to-localize-insulin-production-in-landmark-agreement 2025-05-16T22:43:18+00:00 hourly 0.9 https://trial.medpath.com/news/fda-recalls-nearly-76000-cases-of-eye-care-products-due-to-manufacturing-deviations 2025-05-16T22:16:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-recalls-nearly-76000-cases-of-eye-care-products-due-to-manufacturing-deviations 2025-05-16T22:16:37+00:00 hourly 0.9 https://trial.medpath.com/news/brainomix-s-e-lung-ai-technology-validated-for-progressive-pulmonary-fibrosis-detection-in-boehringer-ingelheim-collaboration 2025-05-16T21:42:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brainomix-s-e-lung-ai-technology-validated-for-progressive-pulmonary-fibrosis-detection-in-boehringer-ingelheim-collaboration 2025-05-16T21:42:20+00:00 hourly 0.9 https://trial.medpath.com/news/revolution-medicines-advances-first-in-class-kras-g12d-molecular-glue-inhibitor-rmc-9805-with-novel-cyclophilin-a-mechanism 2025-05-16T21:41:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/revolution-medicines-advances-first-in-class-kras-g12d-molecular-glue-inhibitor-rmc-9805-with-novel-cyclophilin-a-mechanism 2025-05-16T21:41:26+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-advances-oncology-pipeline-with-first-dosing-in-phase-1-trial-of-novel-mrna-cancer-therapy 2025-05-16T20:40:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moderna-advances-oncology-pipeline-with-first-dosing-in-phase-1-trial-of-novel-mrna-cancer-therapy 2025-05-16T20:40:23+00:00 hourly 0.9 https://trial.medpath.com/news/denosumab-shows-promise-as-immune-modulator-in-breast-cancer-treatment 2025-05-16T20:40:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/denosumab-shows-promise-as-immune-modulator-in-breast-cancer-treatment 2025-05-16T20:40:15+00:00 hourly 0.9 https://trial.medpath.com/news/lamassu-biotech-partners-with-ohio-state-university-for-dual-species-acute-pancreatitis-treatment-development 2025-05-16T20:39:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lamassu-biotech-partners-with-ohio-state-university-for-dual-species-acute-pancreatitis-treatment-development 2025-05-16T20:39:32+00:00 hourly 0.9 https://trial.medpath.com/news/nice-extends-access-to-brineura-for-cln2-batten-disease-while-seeking-long-term-solution 2025-05-16T20:39:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nice-extends-access-to-brineura-for-cln2-batten-disease-while-seeking-long-term-solution 2025-05-16T20:39:18+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-receives-cdsco-approval-for-phase-iiib-trial-of-asciminib-in-chronic-myeloid-leukemia 2025-05-16T20:38:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-receives-cdsco-approval-for-phase-iiib-trial-of-asciminib-in-chronic-myeloid-leukemia 2025-05-16T20:38:25+00:00 hourly 0.9 https://trial.medpath.com/news/biocon-plans-4500-crore-qip-to-reduce-debt-and-increase-biologics-stake 2025-05-16T20:38:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocon-plans-4500-crore-qip-to-reduce-debt-and-increase-biologics-stake 2025-05-16T20:38:22+00:00 hourly 0.9 https://trial.medpath.com/news/biocardia-advances-cardiac-cell-therapy-toward-fda-and-pmda-submissions-despite-primary-endpoint-miss 2025-05-16T20:37:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocardia-advances-cardiac-cell-therapy-toward-fda-and-pmda-submissions-despite-primary-endpoint-miss 2025-05-16T20:37:13+00:00 hourly 0.9 https://trial.medpath.com/news/rosaline-trial-neoadjuvant-letrozole-entrectinib-shows-limited-efficacy-in-invasive-lobular-breast-cancer 2025-05-16T20:36:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rosaline-trial-neoadjuvant-letrozole-entrectinib-shows-limited-efficacy-in-invasive-lobular-breast-cancer 2025-05-16T20:36:35+00:00 hourly 0.9 https://trial.medpath.com/news/cansino-s-inhaled-tb-booster-vaccine-advances-with-clinical-trial-approval-in-indonesia 2025-05-16T19:40:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cansino-s-inhaled-tb-booster-vaccine-advances-with-clinical-trial-approval-in-indonesia 2025-05-16T19:40:58+00:00 hourly 0.9 https://trial.medpath.com/news/align-technology-s-invisalign-palatal-expander-system-receives-nmpa-approval-in-china 2025-05-16T17:41:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/align-technology-s-invisalign-palatal-expander-system-receives-nmpa-approval-in-china 2025-05-16T17:41:23+00:00 hourly 0.9 https://trial.medpath.com/news/skin-cancer-awareness-month-multimodal-approaches-and-prevention-strategies-highlighted-by-experts 2025-05-16T17:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/skin-cancer-awareness-month-multimodal-approaches-and-prevention-strategies-highlighted-by-experts 2025-05-16T17:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-ceo-lars-fruergaard-jorgensen-to-step-down-after-eight-year-tenure 2025-05-16T16:50:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-ceo-lars-fruergaard-jorgensen-to-step-down-after-eight-year-tenure 2025-05-16T16:50:30+00:00 hourly 0.9 https://trial.medpath.com/news/acquired-hemophilia-a-pipeline-expands-with-10-novel-therapies-in-development 2025-05-16T16:49:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acquired-hemophilia-a-pipeline-expands-with-10-novel-therapies-in-development 2025-05-16T16:49:28+00:00 hourly 0.9 https://trial.medpath.com/news/acadia-pharmaceuticals-secures-patent-victory-for-parkinson-s-drug-nuplazid-until-2038 2025-05-16T16:48:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acadia-pharmaceuticals-secures-patent-victory-for-parkinson-s-drug-nuplazid-until-2038 2025-05-16T16:48:52+00:00 hourly 0.9 https://trial.medpath.com/news/acadia-pharmaceuticals-wins-patent-infringement-case-against-aurobindo-for-parkinson-s-drug-nuplazid 2025-05-16T16:48:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acadia-pharmaceuticals-wins-patent-infringement-case-against-aurobindo-for-parkinson-s-drug-nuplazid 2025-05-16T16:48:49+00:00 hourly 0.9 https://trial.medpath.com/news/neurogene-unveils-protocol-to-reverse-hlh-syndrome-associated-with-high-dose-aav-gene-therapy 2025-05-16T16:48:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurogene-unveils-protocol-to-reverse-hlh-syndrome-associated-with-high-dose-aav-gene-therapy 2025-05-16T16:48:47+00:00 hourly 0.9 https://trial.medpath.com/news/acuitas-therapeutics-and-chop-pioneer-personalized-crispr-therapy-for-infant-with-urea-cycle-disorder 2025-05-16T16:48:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acuitas-therapeutics-and-chop-pioneer-personalized-crispr-therapy-for-infant-with-urea-cycle-disorder 2025-05-16T16:48:39+00:00 hourly 0.9 https://trial.medpath.com/news/levothyroxine-trial-to-evaluate-cardiovascular-benefits-in-elderly-with-subclinical-hypothyroidism 2025-05-16T16:47:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/levothyroxine-trial-to-evaluate-cardiovascular-benefits-in-elderly-with-subclinical-hypothyroidism 2025-05-16T16:47:49+00:00 hourly 0.9 https://trial.medpath.com/news/paratek-to-present-groundbreaking-clinical-data-on-nuzyra-for-ntm-and-cabp-at-ats-2025 2025-05-16T16:47:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/paratek-to-present-groundbreaking-clinical-data-on-nuzyra-for-ntm-and-cabp-at-ats-2025 2025-05-16T16:47:10+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-sirna-drug-sns812-for-covid-19-selected-for-prestigious-ats-2025-presentation 2025-05-16T16:47:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-sirna-drug-sns812-for-covid-19-selected-for-prestigious-ats-2025-presentation 2025-05-16T16:47:07+00:00 hourly 0.9 https://trial.medpath.com/news/bluesphere-bio-appoints-immunotherapy-pioneer-alan-korman-as-chief-scientific-officer 2025-05-16T16:46:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bluesphere-bio-appoints-immunotherapy-pioneer-alan-korman-as-chief-scientific-officer 2025-05-16T16:46:40+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-sun-pharma-s-next-generation-led-blu-u-device-for-actinic-keratosis-treatment 2025-05-16T16:09:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-sun-pharma-s-next-generation-led-blu-u-device-for-actinic-keratosis-treatment 2025-05-16T16:09:54+00:00 hourly 0.9 https://trial.medpath.com/news/stanford-medicine-gene-therapy-skin-grafts-show-81-healing-rate-in-phase-3-epidermolysis-bullosa-trial 2025-05-16T16:09:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stanford-medicine-gene-therapy-skin-grafts-show-81-healing-rate-in-phase-3-epidermolysis-bullosa-trial 2025-05-16T16:09:43+00:00 hourly 0.9 https://trial.medpath.com/news/mestastop-solutions-seeks-approval-for-phase-ii-trial-targeting-colorectal-cancer-metastasis 2025-05-16T16:08:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mestastop-solutions-seeks-approval-for-phase-ii-trial-targeting-colorectal-cancer-metastasis 2025-05-16T16:08:56+00:00 hourly 0.9 https://trial.medpath.com/news/corrigendum-published-for-pragmatic-cluster-randomized-clinical-trial-in-endocrinology 2025-05-16T16:08:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/corrigendum-published-for-pragmatic-cluster-randomized-clinical-trial-in-endocrinology 2025-05-16T16:08:24+00:00 hourly 0.9 https://trial.medpath.com/news/iqvia-and-sarah-cannon-research-institute-partner-to-transform-global-oncology-clinical-trials 2025-05-16T16:08:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iqvia-and-sarah-cannon-research-institute-partner-to-transform-global-oncology-clinical-trials 2025-05-16T16:08:22+00:00 hourly 0.9 https://trial.medpath.com/news/world-s-first-patient-receives-personalized-crispr-gene-editing-therapy-at-children-s-hospital-of-philadelphia 2025-05-16T16:08:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/world-s-first-patient-receives-personalized-crispr-gene-editing-therapy-at-children-s-hospital-of-philadelphia 2025-05-16T16:08:16+00:00 hourly 0.9 https://trial.medpath.com/news/first-european-patients-receive-accelerator-based-boron-neutron-capture-therapy-for-head-and-neck-cancer 2025-05-16T15:41:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-european-patients-receive-accelerator-based-boron-neutron-capture-therapy-for-head-and-neck-cancer 2025-05-16T15:41:54+00:00 hourly 0.9 https://trial.medpath.com/news/cadence-and-medera-launch-asia-s-first-multi-centre-gene-therapy-trial-for-heart-failure-in-singapore 2025-05-16T13:35:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cadence-and-medera-launch-asia-s-first-multi-centre-gene-therapy-trial-for-heart-failure-in-singapore 2025-05-16T13:35:16+00:00 hourly 0.9 https://trial.medpath.com/news/biomarin-acquires-inozyme-pharma-for-270-million-adding-late-stage-enzyme-therapy-for-rare-genetic-disorder 2025-05-16T13:12:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomarin-acquires-inozyme-pharma-for-270-million-adding-late-stage-enzyme-therapy-for-rare-genetic-disorder 2025-05-16T13:12:21+00:00 hourly 0.9 https://trial.medpath.com/news/india-launches-fifth-round-of-pli-scheme-for-bulk-drug-manufacturing-to-reduce-import-dependence 2025-05-16T12:45:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-launches-fifth-round-of-pli-scheme-for-bulk-drug-manufacturing-to-reduce-import-dependence 2025-05-16T12:45:24+00:00 hourly 0.9 https://trial.medpath.com/news/once-weekly-secnidazole-shows-superior-efficacy-for-recurrent-bacterial-vaginosis-treatment 2025-05-16T12:44:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/once-weekly-secnidazole-shows-superior-efficacy-for-recurrent-bacterial-vaginosis-treatment 2025-05-16T12:44:19+00:00 hourly 0.9 https://trial.medpath.com/news/ethris-and-lonza-partner-to-develop-room-temperature-stable-spray-dried-mrna-vaccines 2025-05-16T12:44:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ethris-and-lonza-partner-to-develop-room-temperature-stable-spray-dried-mrna-vaccines 2025-05-16T12:44:09+00:00 hourly 0.9 https://trial.medpath.com/news/alectinib-plus-bevacizumab-shows-promising-results-in-first-line-treatment-of-alk-positive-nsclc 2025-05-16T12:43:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alectinib-plus-bevacizumab-shows-promising-results-in-first-line-treatment-of-alk-positive-nsclc 2025-05-16T12:43:28+00:00 hourly 0.9 https://trial.medpath.com/news/gh001-shows-promising-results-in-phase-2b-trial-for-treatment-resistant-depression 2025-05-16T12:42:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gh001-shows-promising-results-in-phase-2b-trial-for-treatment-resistant-depression 2025-05-16T12:42:20+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-receives-swiss-approval-for-first-malaria-treatment-designed-for-newborns-and-infants 2025-05-16T12:12:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-receives-swiss-approval-for-first-malaria-treatment-designed-for-newborns-and-infants 2025-05-16T12:12:14+00:00 hourly 0.9 https://trial.medpath.com/news/landmark-study-confirms-liver-health-biomarker-ct1-predicts-cardiac-and-liver-outcomes 2025-05-16T11:41:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/landmark-study-confirms-liver-health-biomarker-ct1-predicts-cardiac-and-liver-outcomes 2025-05-16T11:41:09+00:00 hourly 0.9 https://trial.medpath.com/news/riliprubart-shows-promise-in-cidp-treatment-with-significant-neurofilament-light-reduction 2025-05-16T09:41:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/riliprubart-shows-promise-in-cidp-treatment-with-significant-neurofilament-light-reduction 2025-05-16T09:41:24+00:00 hourly 0.9 https://trial.medpath.com/news/rakovina-therapeutics-secures-4m-strategic-financing-to-advance-ai-powered-cancer-drug-discovery-platform 2025-05-16T09:41:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rakovina-therapeutics-secures-4m-strategic-financing-to-advance-ai-powered-cancer-drug-discovery-platform 2025-05-16T09:41:08+00:00 hourly 0.9 https://trial.medpath.com/news/inhaled-thc-cbd-combination-shows-superior-efficacy-for-acute-migraine-in-randomized-clinical-trial 2025-05-16T09:33:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inhaled-thc-cbd-combination-shows-superior-efficacy-for-acute-migraine-in-randomized-clinical-trial 2025-05-16T09:33:09+00:00 hourly 0.9 https://trial.medpath.com/news/biodesix-presents-new-data-showing-nodify-lung-r-tests-improve-pulmonary-nodule-management 2025-05-16T08:44:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biodesix-presents-new-data-showing-nodify-lung-r-tests-improve-pulmonary-nodule-management 2025-05-16T08:44:49+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-wins-407-million-in-landmark-antitrust-case-against-amgen-over-pcsk9-drug-market 2025-05-16T08:44:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regeneron-wins-407-million-in-landmark-antitrust-case-against-amgen-over-pcsk9-drug-market 2025-05-16T08:44:34+00:00 hourly 0.9 https://trial.medpath.com/news/avacta-s-pre-cision-technology-makes-toxic-chemotherapy-safer-and-more-effective 2025-05-16T08:44:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avacta-s-pre-cision-technology-makes-toxic-chemotherapy-safer-and-more-effective 2025-05-16T08:44:01+00:00 hourly 0.9 https://trial.medpath.com/news/medvital-secures-8-4-crore-pre-seed-funding-to-transform-wound-care-and-skin-regeneration-in-india 2025-05-16T08:43:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medvital-secures-8-4-crore-pre-seed-funding-to-transform-wound-care-and-skin-regeneration-in-india 2025-05-16T08:43:15+00:00 hourly 0.9 https://trial.medpath.com/news/china-approves-xuanyuening-bireociclib-first-dual-indication-cdk-inhibitor-for-advanced-breast-cancer 2025-05-16T08:12:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-approves-xuanyuening-bireociclib-first-dual-indication-cdk-inhibitor-for-advanced-breast-cancer 2025-05-16T08:12:51+00:00 hourly 0.9 https://trial.medpath.com/news/innate-pharma-s-novel-nk-cell-engager-iph6501-to-be-presented-at-eha-2025-congress 2025-05-16T07:40:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innate-pharma-s-novel-nk-cell-engager-iph6501-to-be-presented-at-eha-2025-congress 2025-05-16T07:40:40+00:00 hourly 0.9 https://trial.medpath.com/news/senseonics-secures-75-million-in-funding-to-accelerate-eversense-365-cgm-launch 2025-05-16T06:35:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/senseonics-secures-75-million-in-funding-to-accelerate-eversense-365-cgm-launch 2025-05-16T06:35:23+00:00 hourly 0.9 https://trial.medpath.com/news/mindfulness-based-cognitive-therapy-shows-promise-for-treatment-resistant-depression 2025-05-16T06:13:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mindfulness-based-cognitive-therapy-shows-promise-for-treatment-resistant-depression 2025-05-16T06:13:10+00:00 hourly 0.9 https://trial.medpath.com/news/uro-1-s-surecore-biopsy-system-shows-significant-improvement-in-prostate-cancer-diagnostic-accuracy 2025-05-16T06:12:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uro-1-s-surecore-biopsy-system-shows-significant-improvement-in-prostate-cancer-diagnostic-accuracy 2025-05-16T06:12:13+00:00 hourly 0.9 https://trial.medpath.com/news/lupin-receives-fda-approval-for-generic-rivaroxaban-tablets-for-thrombosis-prevention 2025-05-16T05:14:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lupin-receives-fda-approval-for-generic-rivaroxaban-tablets-for-thrombosis-prevention 2025-05-16T05:14:03+00:00 hourly 0.9 https://trial.medpath.com/news/camber-pharmaceuticals-launches-temozolomide-capsules-for-brain-cancer-treatment 2025-05-16T04:35:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/camber-pharmaceuticals-launches-temozolomide-capsules-for-brain-cancer-treatment 2025-05-16T04:35:11+00:00 hourly 0.9 https://trial.medpath.com/news/world-first-clinical-trial-ligo-3d-bioprinting-device-revolutionizes-wound-treatment-using-patient-s-own-cells 2025-05-16T04:14:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/world-first-clinical-trial-ligo-3d-bioprinting-device-revolutionizes-wound-treatment-using-patient-s-own-cells 2025-05-16T04:14:41+00:00 hourly 0.9 https://trial.medpath.com/news/elevated-lipoprotein-a-linked-to-higher-risk-of-recurrent-cardiovascular-events-in-landmark-study 2025-05-16T02:44:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elevated-lipoprotein-a-linked-to-higher-risk-of-recurrent-cardiovascular-events-in-landmark-study 2025-05-16T02:44:32+00:00 hourly 0.9 https://trial.medpath.com/news/tarlatamab-for-sclc-comprehensive-administration-protocol-and-patient-selection-guidelines 2025-05-16T02:11:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tarlatamab-for-sclc-comprehensive-administration-protocol-and-patient-selection-guidelines 2025-05-16T02:11:41+00:00 hourly 0.9 https://trial.medpath.com/news/eu-wide-health-technology-assessment-regulation-set-to-transform-drug-access-across-europe-starting-january-2025 2025-05-16T01:51:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eu-wide-health-technology-assessment-regulation-set-to-transform-drug-access-across-europe-starting-january-2025 2025-05-16T01:51:58+00:00 hourly 0.9 https://trial.medpath.com/news/datavant-acquires-aetion-to-create-end-to-end-real-world-evidence-platform 2025-05-16T01:12:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/datavant-acquires-aetion-to-create-end-to-end-real-world-evidence-platform 2025-05-16T01:12:19+00:00 hourly 0.9 https://trial.medpath.com/news/bausch-health-and-mylan-reach-settlement-agreement-over-generic-ibs-drug-patents 2025-05-16T00:44:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bausch-health-and-mylan-reach-settlement-agreement-over-generic-ibs-drug-patents 2025-05-16T00:44:32+00:00 hourly 0.9 https://trial.medpath.com/news/bendamustine-linked-to-car-t-cell-manufacturing-failures-in-large-b-cell-lymphoma-patients 2025-05-16T00:43:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bendamustine-linked-to-car-t-cell-manufacturing-failures-in-large-b-cell-lymphoma-patients 2025-05-16T00:43:09+00:00 hourly 0.9 https://trial.medpath.com/news/aptamer-group-secures-new-development-contracts-and-licensing-deal-for-synthetic-antibody-alternatives 2025-05-16T00:42:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aptamer-group-secures-new-development-contracts-and-licensing-deal-for-synthetic-antibody-alternatives 2025-05-16T00:42:08+00:00 hourly 0.9 https://trial.medpath.com/news/innovent-initiates-head-to-head-phase-3-trial-of-mazdutide-vs-semaglutide-for-obesity-with-fatty-liver-disease 2025-05-16T00:13:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innovent-initiates-head-to-head-phase-3-trial-of-mazdutide-vs-semaglutide-for-obesity-with-fatty-liver-disease 2025-05-16T00:13:46+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-therapies-set-to-transform-eosinophilic-esophagitis-treatment-landscape 2025-05-16T00:13:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-therapies-set-to-transform-eosinophilic-esophagitis-treatment-landscape 2025-05-16T00:13:37+00:00 hourly 0.9 https://trial.medpath.com/news/fda-to-release-new-regulatory-framework-for-vaccine-makers-within-weeks 2025-05-16T00:12:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-to-release-new-regulatory-framework-for-vaccine-makers-within-weeks 2025-05-16T00:12:57+00:00 hourly 0.9 https://trial.medpath.com/news/agc-biologics-and-quell-therapeutics-partner-to-advance-t-regulatory-cell-therapies-for-immune-disorders 2025-05-16T00:12:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/agc-biologics-and-quell-therapeutics-partner-to-advance-t-regulatory-cell-therapies-for-immune-disorders 2025-05-16T00:12:56+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-receptor-agonists-show-significant-survival-benefits-in-diabetic-patients-after-heart-attack-pci 2025-05-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glp-1-receptor-agonists-show-significant-survival-benefits-in-diabetic-patients-after-heart-attack-pci 2025-05-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-soft-auditory-brainstem-implant-shows-promise-for-neurofibromatosis-type-2-patients 2025-05-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-soft-auditory-brainstem-implant-shows-promise-for-neurofibromatosis-type-2-patients 2025-05-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-launches-systematic-postmarket-chemical-review-program-to-enhance-food-safety 2025-05-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-launches-systematic-postmarket-chemical-review-program-to-enhance-food-safety 2025-05-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/medicines-discovery-catapult-expands-strategic-partnerships-to-accelerate-uk-drug-discovery-innovation 2025-05-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medicines-discovery-catapult-expands-strategic-partnerships-to-accelerate-uk-drug-discovery-innovation 2025-05-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-and-gilead-secure-eu-approval-for-next-generation-hepatitis-c-therapies-targeting-treatment-resistant-patients 2025-05-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-and-gilead-secure-eu-approval-for-next-generation-hepatitis-c-therapies-targeting-treatment-resistant-patients 2025-05-16T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/atara-biotherapeutics-secures-16-million-funding-to-advance-tab-cel-bla-approval 2025-05-15T22:41:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atara-biotherapeutics-secures-16-million-funding-to-advance-tab-cel-bla-approval 2025-05-15T22:41:27+00:00 hourly 0.9 https://trial.medpath.com/news/calcutta-high-court-overturns-patent-rejection-for-nicotine-aerosol-device-clarifies-public-health-exception-limits 2025-05-15T22:14:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/calcutta-high-court-overturns-patent-rejection-for-nicotine-aerosol-device-clarifies-public-health-exception-limits 2025-05-15T22:14:55+00:00 hourly 0.9 https://trial.medpath.com/news/singapore-biotech-mirxes-achieves-1-billion-valuation-with-hong-kong-ipo-becomes-first-southeast-asian-unicorn 2025-05-15T21:13:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/singapore-biotech-mirxes-achieves-1-billion-valuation-with-hong-kong-ipo-becomes-first-southeast-asian-unicorn 2025-05-15T21:13:00+00:00 hourly 0.9 https://trial.medpath.com/news/hengrui-pharmaceuticals-aims-to-raise-1-27-billion-in-hong-kong-ipo 2025-05-15T21:12:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hengrui-pharmaceuticals-aims-to-raise-1-27-billion-in-hong-kong-ipo 2025-05-15T21:12:28+00:00 hourly 0.9 https://trial.medpath.com/news/genvivo-reports-promising-phase-1-data-for-gen2-and-preclinical-results-for-gen-1013-cancer-immunotherapies-at-asgct-2025 2025-05-15T20:47:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genvivo-reports-promising-phase-1-data-for-gen2-and-preclinical-results-for-gen-1013-cancer-immunotherapies-at-asgct-2025 2025-05-15T20:47:15+00:00 hourly 0.9 https://trial.medpath.com/news/sparx-biopharmaceutical-and-mitsubishi-tanabe-pharma-america-partner-on-novel-immune-cell-targeting-adc-program 2025-05-15T20:47:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sparx-biopharmaceutical-and-mitsubishi-tanabe-pharma-america-partner-on-novel-immune-cell-targeting-adc-program 2025-05-15T20:47:07+00:00 hourly 0.9 https://trial.medpath.com/news/pulmatrix-to-divest-phase-2-ready-migraine-treatment-and-isperse-technology-ahead-of-cullgen-merger 2025-05-15T20:47:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pulmatrix-to-divest-phase-2-ready-migraine-treatment-and-isperse-technology-ahead-of-cullgen-merger 2025-05-15T20:47:02+00:00 hourly 0.9 https://trial.medpath.com/news/abbott-s-freestyle-libre-cgm-system-reduces-cardiovascular-hospitalization-risk-in-diabetes-patients 2025-05-15T20:47:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbott-s-freestyle-libre-cgm-system-reduces-cardiovascular-hospitalization-risk-in-diabetes-patients 2025-05-15T20:47:01+00:00 hourly 0.9 https://trial.medpath.com/news/affluent-medical-s-artus-device-shows-87-reduction-in-urinary-leakage-advances-to-pivotal-trial-phase 2025-05-15T20:45:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/affluent-medical-s-artus-device-shows-87-reduction-in-urinary-leakage-advances-to-pivotal-trial-phase 2025-05-15T20:45:04+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-cancer-drug-approvals-to-abbvie-and-msd-abbvie-announces-335m-adarx-partnership 2025-05-15T20:44:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-cancer-drug-approvals-to-abbvie-and-msd-abbvie-announces-335m-adarx-partnership 2025-05-15T20:44:31+00:00 hourly 0.9 https://trial.medpath.com/news/redica-systems-secures-new-financing-to-enhance-ai-driven-quality-intelligence-in-life-sciences 2025-05-15T20:44:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/redica-systems-secures-new-financing-to-enhance-ai-driven-quality-intelligence-in-life-sciences 2025-05-15T20:44:20+00:00 hourly 0.9 https://trial.medpath.com/news/uva-health-develops-breakthrough-non-invasive-ultrasound-treatment-for-cerebral-cavernous-malformations 2025-05-15T20:15:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uva-health-develops-breakthrough-non-invasive-ultrasound-treatment-for-cerebral-cavernous-malformations 2025-05-15T20:15:47+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-first-personalized-mrna-based-crispr-therapy-successfully-treats-infant-with-rare-metabolic-disorder 2025-05-15T20:14:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-first-personalized-mrna-based-crispr-therapy-successfully-treats-infant-with-rare-metabolic-disorder 2025-05-15T20:14:06+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-partners-with-rznomics-in-1-3b-deal-to-develop-rna-editing-therapy-for-hereditary-hearing-loss 2025-05-15T20:14:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-partners-with-rznomics-in-1-3b-deal-to-develop-rna-editing-therapy-for-hereditary-hearing-loss 2025-05-15T20:14:04+00:00 hourly 0.9 https://trial.medpath.com/news/critical-limb-ischemia-market-projected-to-reach-2-5-billion-by-2035-driven-by-novel-therapies-and-advanced-diagnostics 2025-05-15T20:14:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/critical-limb-ischemia-market-projected-to-reach-2-5-billion-by-2035-driven-by-novel-therapies-and-advanced-diagnostics 2025-05-15T20:14:03+00:00 hourly 0.9 https://trial.medpath.com/news/forward-science-launches-periostom-fda-cleared-chitosan-based-wound-dressing-for-periodontal-care 2025-05-15T20:13:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/forward-science-launches-periostom-fda-cleared-chitosan-based-wound-dressing-for-periodontal-care 2025-05-15T20:13:12+00:00 hourly 0.9 https://trial.medpath.com/news/abm-respiratory-care-launches-home-study-of-biwaze-clear-system-for-bronchiectasis-patients 2025-05-15T20:13:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abm-respiratory-care-launches-home-study-of-biwaze-clear-system-for-bronchiectasis-patients 2025-05-15T20:13:01+00:00 hourly 0.9 https://trial.medpath.com/news/uk-launches-pilot-program-for-diversity-plans-in-drug-and-medical-device-trials 2025-05-15T20:12:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-launches-pilot-program-for-diversity-plans-in-drug-and-medical-device-trials 2025-05-15T20:12:57+00:00 hourly 0.9 https://trial.medpath.com/news/hiv-vaccine-breakthrough-clinical-trials-show-promise-for-broadly-neutralizing-antibody-development 2025-05-15T20:12:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hiv-vaccine-breakthrough-clinical-trials-show-promise-for-broadly-neutralizing-antibody-development 2025-05-15T20:12:56+00:00 hourly 0.9 https://trial.medpath.com/news/upc-issues-landmark-ruling-on-second-medical-use-patents-in-cholesterol-drug-dispute 2025-05-15T19:14:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/upc-issues-landmark-ruling-on-second-medical-use-patents-in-cholesterol-drug-dispute 2025-05-15T19:14:32+00:00 hourly 0.9 https://trial.medpath.com/news/elix-and-prism-biolab-form-strategic-partnership-for-ai-driven-drug-discovery 2025-05-15T18:41:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elix-and-prism-biolab-form-strategic-partnership-for-ai-driven-drug-discovery 2025-05-15T18:41:15+00:00 hourly 0.9 https://trial.medpath.com/news/peptisystems-and-asahi-kasei-bioprocess-america-form-strategic-partnership-to-revolutionize-peptide-manufacturing 2025-05-15T18:14:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/peptisystems-and-asahi-kasei-bioprocess-america-form-strategic-partnership-to-revolutionize-peptide-manufacturing 2025-05-15T18:14:31+00:00 hourly 0.9 https://trial.medpath.com/news/colorectal-cancer-leads-in-real-world-data-volume-but-oncology-trials-need-modernization 2025-05-15T17:44:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/colorectal-cancer-leads-in-real-world-data-volume-but-oncology-trials-need-modernization 2025-05-15T17:44:30+00:00 hourly 0.9 https://trial.medpath.com/news/crispr-gene-editing-breakthrough-saves-baby-with-ultra-rare-metabolic-disorder 2025-05-15T17:43:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crispr-gene-editing-breakthrough-saves-baby-with-ultra-rare-metabolic-disorder 2025-05-15T17:43:13+00:00 hourly 0.9 https://trial.medpath.com/news/new-study-shows-taf-and-dolutegravir-superior-for-second-line-hiv-treatment-in-children 2025-05-15T17:06:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-study-shows-taf-and-dolutegravir-superior-for-second-line-hiv-treatment-in-children 2025-05-15T17:06:14+00:00 hourly 0.9 https://trial.medpath.com/news/agilent-and-ubix-therapeutics-form-5-year-partnership-to-advance-targeted-cancer-therapies-in-south-korea 2025-05-15T16:45:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/agilent-and-ubix-therapeutics-form-5-year-partnership-to-advance-targeted-cancer-therapies-in-south-korea 2025-05-15T16:45:57+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-gene-editing-therapy-successfully-treats-infant-with-rare-metabolic-disorder 2025-05-15T16:43:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-gene-editing-therapy-successfully-treats-infant-with-rare-metabolic-disorder 2025-05-15T16:43:43+00:00 hourly 0.9 https://trial.medpath.com/news/klothea-bio-and-healthy-longevity-clinic-partner-to-advance-mrna-based-klotho-therapies-for-aging 2025-05-15T16:43:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/klothea-bio-and-healthy-longevity-clinic-partner-to-advance-mrna-based-klotho-therapies-for-aging 2025-05-15T16:43:42+00:00 hourly 0.9 https://trial.medpath.com/news/biomea-fusion-s-bmf-500-shows-promising-results-in-relapsed-refractory-acute-leukemia-phase-i-trial 2025-05-15T16:43:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomea-fusion-s-bmf-500-shows-promising-results-in-relapsed-refractory-acute-leukemia-phase-i-trial 2025-05-15T16:43:29+00:00 hourly 0.9 https://trial.medpath.com/news/genflow-biosciences-advances-sirt6-patent-applications-in-europe-and-japan-for-age-related-disease-therapies 2025-05-15T16:42:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genflow-biosciences-advances-sirt6-patent-applications-in-europe-and-japan-for-age-related-disease-therapies 2025-05-15T16:42:50+00:00 hourly 0.9 https://trial.medpath.com/news/upc-sets-precedent-in-first-second-medical-use-patent-ruling-sanofi-and-regeneron-lose-against-amgen 2025-05-15T16:42:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/upc-sets-precedent-in-first-second-medical-use-patent-ruling-sanofi-and-regeneron-lose-against-amgen 2025-05-15T16:42:48+00:00 hourly 0.9 https://trial.medpath.com/news/ukraine-adopts-bolar-rule-to-accelerate-generic-drug-market-entry 2025-05-15T16:42:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ukraine-adopts-bolar-rule-to-accelerate-generic-drug-market-entry 2025-05-15T16:42:20+00:00 hourly 0.9 https://trial.medpath.com/news/orna-therapeutics-demonstrates-promising-results-for-in-vivo-car-therapy-in-autoimmune-diseases 2025-05-15T16:41:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orna-therapeutics-demonstrates-promising-results-for-in-vivo-car-therapy-in-autoimmune-diseases 2025-05-15T16:41:41+00:00 hourly 0.9 https://trial.medpath.com/news/intermountain-health-pioneers-first-remote-car-t-cell-collection-site-in-southern-utah 2025-05-15T16:41:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intermountain-health-pioneers-first-remote-car-t-cell-collection-site-in-southern-utah 2025-05-15T16:41:39+00:00 hourly 0.9 https://trial.medpath.com/news/rybodyn-expands-collaboration-with-moffitt-cancer-center-to-advance-novel-dark-proteome-cancer-immunotherapies 2025-05-15T16:41:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rybodyn-expands-collaboration-with-moffitt-cancer-center-to-advance-novel-dark-proteome-cancer-immunotherapies 2025-05-15T16:41:37+00:00 hourly 0.9 https://trial.medpath.com/news/sona-nanotech-s-gold-nanorods-pass-critical-endotoxin-testing-ahead-of-first-human-cancer-trial 2025-05-15T16:41:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sona-nanotech-s-gold-nanorods-pass-critical-endotoxin-testing-ahead-of-first-human-cancer-trial 2025-05-15T16:41:30+00:00 hourly 0.9 https://trial.medpath.com/news/alamar-biosciences-revolutionizes-alzheimer-s-detection-with-blood-based-brain-derived-tau-assays 2025-05-15T16:41:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alamar-biosciences-revolutionizes-alzheimer-s-detection-with-blood-based-brain-derived-tau-assays 2025-05-15T16:41:09+00:00 hourly 0.9 https://trial.medpath.com/news/kincell-bio-secures-22-million-investment-to-expand-cell-therapy-manufacturing-capabilities 2025-05-15T16:40:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kincell-bio-secures-22-million-investment-to-expand-cell-therapy-manufacturing-capabilities 2025-05-15T16:40:46+00:00 hourly 0.9 https://trial.medpath.com/news/steerlife-unveils-solvent-free-melt-fusion-technology-for-potent-drug-development 2025-05-15T16:39:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/steerlife-unveils-solvent-free-melt-fusion-technology-for-potent-drug-development 2025-05-15T16:39:57+00:00 hourly 0.9 https://trial.medpath.com/news/ema-s-pdco-endorses-poltreg-s-pediatric-investigation-plan-for-novel-type-1-diabetes-cell-therapy 2025-05-15T16:38:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-s-pdco-endorses-poltreg-s-pediatric-investigation-plan-for-novel-type-1-diabetes-cell-therapy 2025-05-15T16:38:02+00:00 hourly 0.9 https://trial.medpath.com/news/elucent-medical-s-envisio-x1-surgical-navigation-system-receives-fda-breakthrough-device-designation 2025-05-15T16:11:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elucent-medical-s-envisio-x1-surgical-navigation-system-receives-fda-breakthrough-device-designation 2025-05-15T16:11:49+00:00 hourly 0.9 https://trial.medpath.com/news/pathos-ai-raises-365-million-to-advance-ai-driven-oncology-drug-development 2025-05-15T16:11:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pathos-ai-raises-365-million-to-advance-ai-driven-oncology-drug-development 2025-05-15T16:11:35+00:00 hourly 0.9 https://trial.medpath.com/news/optymedge-unveils-first-dedicated-ophthalmology-clinical-trial-platform-at-arvo-2025 2025-05-15T16:10:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/optymedge-unveils-first-dedicated-ophthalmology-clinical-trial-platform-at-arvo-2025 2025-05-15T16:10:23+00:00 hourly 0.9 https://trial.medpath.com/news/pharmala-biotech-unveils-phenesafe-ai-platform-to-accelerate-mdxx-drug-discovery 2025-05-15T16:10:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmala-biotech-unveils-phenesafe-ai-platform-to-accelerate-mdxx-drug-discovery 2025-05-15T16:10:21+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-brekiya-first-dhe-autoinjector-for-acute-migraine-and-cluster-headache-treatment 2025-05-15T16:10:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-brekiya-first-dhe-autoinjector-for-acute-migraine-and-cluster-headache-treatment 2025-05-15T16:10:19+00:00 hourly 0.9 https://trial.medpath.com/news/first-u-s-patient-dosed-in-moderna-s-phase-1-trial-of-novel-mrna-4106-pan-tumor-therapy 2025-05-15T16:06:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-u-s-patient-dosed-in-moderna-s-phase-1-trial-of-novel-mrna-4106-pan-tumor-therapy 2025-05-15T16:06:15+00:00 hourly 0.9 https://trial.medpath.com/news/biovie-initiates-phase-2-trial-of-bezisterim-for-long-covid-neurological-symptoms 2025-05-15T16:06:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biovie-initiates-phase-2-trial-of-bezisterim-for-long-covid-neurological-symptoms 2025-05-15T16:06:11+00:00 hourly 0.9 https://trial.medpath.com/news/regulatory-immune-cells-emerge-as-key-therapeutic-targets-in-immunotherapy-and-autoimmune-disease-treatment 2025-05-15T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regulatory-immune-cells-emerge-as-key-therapeutic-targets-in-immunotherapy-and-autoimmune-disease-treatment 2025-05-15T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/shilpa-medicare-receives-usfda-clearance-for-bengaluru-manufacturing-unit 2025-05-15T14:58:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shilpa-medicare-receives-usfda-clearance-for-bengaluru-manufacturing-unit 2025-05-15T14:58:00+00:00 hourly 0.9 https://trial.medpath.com/news/bendigo-patient-first-in-australia-to-trial-novel-prostate-cancer-drug-that-could-delay-chemotherapy 2025-05-15T13:42:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bendigo-patient-first-in-australia-to-trial-novel-prostate-cancer-drug-that-could-delay-chemotherapy 2025-05-15T13:42:09+00:00 hourly 0.9 https://trial.medpath.com/news/broad-institute-selects-argonaut-to-manufacture-sirna-therapeutic-for-pioneering-prion-disease-trial 2025-05-15T13:05:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/broad-institute-selects-argonaut-to-manufacture-sirna-therapeutic-for-pioneering-prion-disease-trial 2025-05-15T13:05:10+00:00 hourly 0.9 https://trial.medpath.com/news/samuraciclib-shows-promise-in-hr-breast-cancer-patients-without-tp53-mutations-or-liver-metastases 2025-05-15T12:40:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/samuraciclib-shows-promise-in-hr-breast-cancer-patients-without-tp53-mutations-or-liver-metastases 2025-05-15T12:40:25+00:00 hourly 0.9 https://trial.medpath.com/news/european-consortium-secures-eur2-5-million-to-develop-predictive-biomarker-test-for-immunotherapy-response 2025-05-15T12:40:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/european-consortium-secures-eur2-5-million-to-develop-predictive-biomarker-test-for-immunotherapy-response 2025-05-15T12:40:24+00:00 hourly 0.9 https://trial.medpath.com/news/imprint-labs-secures-15m-to-decode-immune-memory-for-chronic-disease-research 2025-05-15T12:40:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imprint-labs-secures-15m-to-decode-immune-memory-for-chronic-disease-research 2025-05-15T12:40:16+00:00 hourly 0.9 https://trial.medpath.com/news/viva-biotech-unveils-ai-driven-drug-discovery-platform-promising-to-cut-development-time-by-50-70 2025-05-15T12:40:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viva-biotech-unveils-ai-driven-drug-discovery-platform-promising-to-cut-development-time-by-50-70 2025-05-15T12:40:04+00:00 hourly 0.9 https://trial.medpath.com/news/quralis-secures-exclusive-license-for-novel-rna-targeted-therapy-in-fragile-x-syndrome 2025-05-15T12:11:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quralis-secures-exclusive-license-for-novel-rna-targeted-therapy-in-fragile-x-syndrome 2025-05-15T12:11:08+00:00 hourly 0.9 https://trial.medpath.com/news/amt-bridle-pro-r-significantly-reduces-feeding-tube-dislodgement-in-pediatric-patients-study-finds 2025-05-15T12:10:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amt-bridle-pro-r-significantly-reduces-feeding-tube-dislodgement-in-pediatric-patients-study-finds 2025-05-15T12:10:46+00:00 hourly 0.9 https://trial.medpath.com/news/immusoft-reports-breakthrough-results-from-first-ever-engineered-b-cell-therapy-in-mps-i-clinical-trial 2025-05-15T11:36:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immusoft-reports-breakthrough-results-from-first-ever-engineered-b-cell-therapy-in-mps-i-clinical-trial 2025-05-15T11:36:06+00:00 hourly 0.9 https://trial.medpath.com/news/nutriband-advances-aversa-fentanyl-patch-development-through-strategic-partnership-with-kindeva-drug-delivery 2025-05-15T11:03:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nutriband-advances-aversa-fentanyl-patch-development-through-strategic-partnership-with-kindeva-drug-delivery 2025-05-15T11:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/imu-biosciences-partners-with-curiox-for-uk-s-largest-immune-profiling-initiative 2025-05-15T10:46:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imu-biosciences-partners-with-curiox-for-uk-s-largest-immune-profiling-initiative 2025-05-15T10:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/beigene-to-present-extensive-hematology-data-at-eha-2025-showcasing-brukinsa-and-next-generation-therapies 2025-05-15T10:08:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beigene-to-present-extensive-hematology-data-at-eha-2025-showcasing-brukinsa-and-next-generation-therapies 2025-05-15T10:08:17+00:00 hourly 0.9 https://trial.medpath.com/news/narmafotinib-combination-shows-superior-response-in-pancreatic-cancer-accent-trial 2025-05-15T10:08:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/narmafotinib-combination-shows-superior-response-in-pancreatic-cancer-accent-trial 2025-05-15T10:08:10+00:00 hourly 0.9 https://trial.medpath.com/news/lava-therapeutics-reports-q1-2025-results-while-restructuring-operations-and-advancing-clinical-trials 2025-05-15T10:07:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lava-therapeutics-reports-q1-2025-results-while-restructuring-operations-and-advancing-clinical-trials 2025-05-15T10:07:58+00:00 hourly 0.9 https://trial.medpath.com/news/jade-biosciences-advances-jade101-anti-april-antibody-for-iga-nephropathy-with-300m-funding 2025-05-15T09:41:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jade-biosciences-advances-jade101-anti-april-antibody-for-iga-nephropathy-with-300m-funding 2025-05-15T09:41:32+00:00 hourly 0.9 https://trial.medpath.com/news/zeno-power-secures-50m-series-b-to-scale-nuclear-battery-production-for-defense-and-space-applications 2025-05-15T09:12:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zeno-power-secures-50m-series-b-to-scale-nuclear-battery-production-for-defense-and-space-applications 2025-05-15T09:12:49+00:00 hourly 0.9 https://trial.medpath.com/news/median-technologies-submits-fda-510-k-application-for-ai-powered-lung-cancer-screening-software 2025-05-15T09:11:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/median-technologies-submits-fda-510-k-application-for-ai-powered-lung-cancer-screening-software 2025-05-15T09:11:53+00:00 hourly 0.9 https://trial.medpath.com/news/sail-biomedicines-advances-novel-in-vivo-erna-car-t-therapy-for-autoimmune-diseases 2025-05-15T09:11:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sail-biomedicines-advances-novel-in-vivo-erna-car-t-therapy-for-autoimmune-diseases 2025-05-15T09:11:46+00:00 hourly 0.9 https://trial.medpath.com/news/nice-approves-capivasertib-fulvestrant-combination-for-advanced-breast-cancer-treatment 2025-05-15T08:43:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nice-approves-capivasertib-fulvestrant-combination-for-advanced-breast-cancer-treatment 2025-05-15T08:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-s-uk-mrna-vaccine-facility-now-fully-operational-in-oxfordshire 2025-05-15T08:39:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moderna-s-uk-mrna-vaccine-facility-now-fully-operational-in-oxfordshire 2025-05-15T08:39:53+00:00 hourly 0.9 https://trial.medpath.com/news/foresee-pharmaceuticals-initiates-phase-2-windward-trial-of-mirivadelgat-for-ph-ild-treatment 2025-05-15T08:39:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/foresee-pharmaceuticals-initiates-phase-2-windward-trial-of-mirivadelgat-for-ph-ild-treatment 2025-05-15T08:39:48+00:00 hourly 0.9 https://trial.medpath.com/news/immunofoco-unveils-novel-in-vivo-car-t-platform-with-enhanced-targeting-and-efficacy-at-asgct-2025 2025-05-15T08:39:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunofoco-unveils-novel-in-vivo-car-t-platform-with-enhanced-targeting-and-efficacy-at-asgct-2025 2025-05-15T08:39:44+00:00 hourly 0.9 https://trial.medpath.com/news/liver-cirrhosis-pipeline-shows-strong-growth-with-30-therapies-in-development-across-multiple-clinical-phases 2025-05-15T08:39:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/liver-cirrhosis-pipeline-shows-strong-growth-with-30-therapies-in-development-across-multiple-clinical-phases 2025-05-15T08:39:34+00:00 hourly 0.9 https://trial.medpath.com/news/onemeta-and-invictus-bpo-form-strategic-partnership-to-revolutionize-multilingual-customer-service 2025-05-15T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/onemeta-and-invictus-bpo-form-strategic-partnership-to-revolutionize-multilingual-customer-service 2025-05-15T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/enedra-therapeutics-secures-new-funding-to-advance-ai-driven-platform-for-difficult-to-treat-cancers 2025-05-15T08:14:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enedra-therapeutics-secures-new-funding-to-advance-ai-driven-platform-for-difficult-to-treat-cancers 2025-05-15T08:14:46+00:00 hourly 0.9 https://trial.medpath.com/news/weight-regain-after-stopping-glp-1-drugs-occurs-within-two-years-oxford-study-reveals 2025-05-15T06:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/weight-regain-after-stopping-glp-1-drugs-occurs-within-two-years-oxford-study-reveals 2025-05-15T06:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/voyager-therapeutics-publishes-breakthrough-research-on-alpl-mediated-blood-brain-barrier-transport-for-gene-therapy 2025-05-15T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/voyager-therapeutics-publishes-breakthrough-research-on-alpl-mediated-blood-brain-barrier-transport-for-gene-therapy 2025-05-15T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/schrodinger-to-present-phase-1-data-on-malt1-inhibitor-sgr-1505-for-relapsed-refractory-b-cell-malignancies 2025-05-15T03:13:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/schrodinger-to-present-phase-1-data-on-malt1-inhibitor-sgr-1505-for-relapsed-refractory-b-cell-malignancies 2025-05-15T03:13:23+00:00 hourly 0.9 https://trial.medpath.com/news/trump-administration-s-drug-pricing-order-targets-glp-1-market-threatening-novo-nordisk-and-eli-lilly-dominance 2025-05-15T02:42:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-administration-s-drug-pricing-order-targets-glp-1-market-threatening-novo-nordisk-and-eli-lilly-dominance 2025-05-15T02:42:22+00:00 hourly 0.9 https://trial.medpath.com/news/telisotuzumab-vedotin-plus-osimertinib-shows-promise-in-tki-resistant-nsclc-with-c-met-overexpression 2025-05-15T02:42:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/telisotuzumab-vedotin-plus-osimertinib-shows-promise-in-tki-resistant-nsclc-with-c-met-overexpression 2025-05-15T02:42:13+00:00 hourly 0.9 https://trial.medpath.com/news/contineum-therapeutics-on-track-for-key-clinical-milestones-with-pipe-791-and-pipe-307-programs 2025-05-15T02:42:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/contineum-therapeutics-on-track-for-key-clinical-milestones-with-pipe-791-and-pipe-307-programs 2025-05-15T02:42:05+00:00 hourly 0.9 https://trial.medpath.com/news/bispecific-antibodies-show-superior-safety-profile-and-efficacy-in-follicular-lymphoma-treatment 2025-05-15T02:41:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bispecific-antibodies-show-superior-safety-profile-and-efficacy-in-follicular-lymphoma-treatment 2025-05-15T02:41:31+00:00 hourly 0.9 https://trial.medpath.com/news/neoadjuvant-immunotherapy-emerges-as-promising-strategy-for-early-stage-nsclc-treatment 2025-05-15T02:40:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neoadjuvant-immunotherapy-emerges-as-promising-strategy-for-early-stage-nsclc-treatment 2025-05-15T02:40:09+00:00 hourly 0.9 https://trial.medpath.com/news/nationwide-study-confirms-safety-of-lumason-r-ultrasound-enhancing-agent-in-echocardiography 2025-05-15T02:19:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nationwide-study-confirms-safety-of-lumason-r-ultrasound-enhancing-agent-in-echocardiography 2025-05-15T02:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/inozyme-s-inz-701-shows-promise-in-enpp1-deficiency-trial-with-sustained-phosphate-increases 2025-05-15T02:09:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inozyme-s-inz-701-shows-promise-in-enpp1-deficiency-trial-with-sustained-phosphate-increases 2025-05-15T02:09:22+00:00 hourly 0.9 https://trial.medpath.com/news/ntxbio-to-establish-31m-biomanufacturing-facility-in-plano-texas-creating-170-jobs 2025-05-15T02:08:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ntxbio-to-establish-31m-biomanufacturing-facility-in-plano-texas-creating-170-jobs 2025-05-15T02:08:15+00:00 hourly 0.9 https://trial.medpath.com/news/julius-clinical-and-peachtree-bioresearch-solutions-merge-to-create-global-cro-with-enhanced-cns-capabilities 2025-05-15T01:38:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/julius-clinical-and-peachtree-bioresearch-solutions-merge-to-create-global-cro-with-enhanced-cns-capabilities 2025-05-15T01:38:52+00:00 hourly 0.9 https://trial.medpath.com/news/novel-nanoparticle-technology-enhances-ultrasound-cancer-treatment-while-reducing-collateral-damage 2025-05-15T01:38:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-nanoparticle-technology-enhances-ultrasound-cancer-treatment-while-reducing-collateral-damage 2025-05-15T01:38:28+00:00 hourly 0.9 https://trial.medpath.com/news/california-proposes-cutting-medi-cal-coverage-for-weight-loss-drugs-to-address-budget-deficit 2025-05-15T00:40:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/california-proposes-cutting-medi-cal-coverage-for-weight-loss-drugs-to-address-budget-deficit 2025-05-15T00:40:55+00:00 hourly 0.9 https://trial.medpath.com/news/yale-study-shows-nasal-vaccine-boosters-effective-without-adjuvants-for-respiratory-disease-protection 2025-05-15T00:40:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/yale-study-shows-nasal-vaccine-boosters-effective-without-adjuvants-for-respiratory-disease-protection 2025-05-15T00:40:43+00:00 hourly 0.9 https://trial.medpath.com/news/trilink-biotechnologies-and-ivi-partner-to-advance-mrna-vaccine-development-for-global-health-equity 2025-05-15T00:40:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trilink-biotechnologies-and-ivi-partner-to-advance-mrna-vaccine-development-for-global-health-equity 2025-05-15T00:40:15+00:00 hourly 0.9 https://trial.medpath.com/news/apimeds-pharmaceuticals-raises-13-5m-in-nyse-american-ipo 2025-05-15T00:40:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/apimeds-pharmaceuticals-raises-13-5m-in-nyse-american-ipo 2025-05-15T00:40:04+00:00 hourly 0.9 https://trial.medpath.com/news/aspen-neuroscience-advances-automated-manufacturing-of-ipsc-derived-therapy-for-parkinson-s-disease 2025-05-15T00:39:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aspen-neuroscience-advances-automated-manufacturing-of-ipsc-derived-therapy-for-parkinson-s-disease 2025-05-15T00:39:14+00:00 hourly 0.9 https://trial.medpath.com/news/takeda-s-oveporexton-shows-promising-results-in-phase-2b-trial-for-narcolepsy-type-1 2025-05-15T00:14:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/takeda-s-oveporexton-shows-promising-results-in-phase-2b-trial-for-narcolepsy-type-1 2025-05-15T00:14:38+00:00 hourly 0.9 https://trial.medpath.com/news/congenital-hyperinsulinism-pipeline-shows-promise-with-multiple-therapies-advancing-through-clinical-development 2025-05-15T00:14:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/congenital-hyperinsulinism-pipeline-shows-promise-with-multiple-therapies-advancing-through-clinical-development 2025-05-15T00:14:27+00:00 hourly 0.9 https://trial.medpath.com/news/chugai-seeks-approval-for-tecentriq-to-treat-rare-thymic-carcinoma-in-japan 2025-05-15T00:12:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chugai-seeks-approval-for-tecentriq-to-treat-rare-thymic-carcinoma-in-japan 2025-05-15T00:12:37+00:00 hourly 0.9 https://trial.medpath.com/news/intratumoral-microbiota-emerges-as-key-player-in-cancer-development-and-treatment-response 2025-05-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intratumoral-microbiota-emerges-as-key-player-in-cancer-development-and-treatment-response 2025-05-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/federal-court-upholds-alexion-patent-blocks-amgen-biosimilar 2025-05-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-court-upholds-alexion-patent-blocks-amgen-biosimilar 2025-05-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/lenalidomide-plus-pd-1-inhibitor-achieves-sustained-remission-in-relapsed-hodgkin-lymphoma-case 2025-05-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lenalidomide-plus-pd-1-inhibitor-achieves-sustained-remission-in-relapsed-hodgkin-lymphoma-case 2025-05-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/genentech-advances-prasinezumab-to-phase-iii-for-early-stage-parkinson-s-disease-following-positive-phase-iib-results 2025-05-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genentech-advances-prasinezumab-to-phase-iii-for-early-stage-parkinson-s-disease-following-positive-phase-iib-results 2025-05-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/heidelberg-pharma-initiates-phase-i-trial-of-hdp-102-for-non-hodgkin-lymphoma-as-second-amanitin-based-adc-enters-clinic 2025-05-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/heidelberg-pharma-initiates-phase-i-trial-of-hdp-102-for-non-hodgkin-lymphoma-as-second-amanitin-based-adc-enters-clinic 2025-05-15T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ecolab-life-sciences-launches-advanced-bioprocessing-applications-lab-in-pennsylvania 2025-05-14T23:41:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ecolab-life-sciences-launches-advanced-bioprocessing-applications-lab-in-pennsylvania 2025-05-14T23:41:37+00:00 hourly 0.9 https://trial.medpath.com/news/nuvig-therapeutics-initiates-phase-2-trial-of-novel-cidp-treatment-nvg-2089 2025-05-14T23:11:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nuvig-therapeutics-initiates-phase-2-trial-of-novel-cidp-treatment-nvg-2089 2025-05-14T23:11:45+00:00 hourly 0.9 https://trial.medpath.com/news/bioinvent-reports-promising-results-from-triple-combination-therapy-for-non-hodgkin-s-lymphoma 2025-05-14T21:44:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioinvent-reports-promising-results-from-triple-combination-therapy-for-non-hodgkin-s-lymphoma 2025-05-14T21:44:19+00:00 hourly 0.9 https://trial.medpath.com/news/atyr-pharma-advances-novel-anti-fibrotic-therapy-atyr0101-for-pulmonary-fibrosis 2025-05-14T21:43:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atyr-pharma-advances-novel-anti-fibrotic-therapy-atyr0101-for-pulmonary-fibrosis 2025-05-14T21:43:09+00:00 hourly 0.9 https://trial.medpath.com/news/plasmidsaurus-unveils-three-day-aav-genome-sequencing-service-to-transform-gene-therapy-development 2025-05-14T21:06:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/plasmidsaurus-unveils-three-day-aav-genome-sequencing-service-to-transform-gene-therapy-development 2025-05-14T21:06:25+00:00 hourly 0.9 https://trial.medpath.com/news/autonomix-medical-to-expand-cancer-pain-management-trial-beyond-pancreatic-cancer-in-q2-2025 2025-05-14T20:44:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/autonomix-medical-to-expand-cancer-pain-management-trial-beyond-pancreatic-cancer-in-q2-2025 2025-05-14T20:44:45+00:00 hourly 0.9 https://trial.medpath.com/news/qihan-biotech-unveils-novel-cytokine-pathway-engineering-for-enhanced-car-t-therapy-without-lymphodepletion 2025-05-14T20:43:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/qihan-biotech-unveils-novel-cytokine-pathway-engineering-for-enhanced-car-t-therapy-without-lymphodepletion 2025-05-14T20:43:50+00:00 hourly 0.9 https://trial.medpath.com/news/eyecool-therapeutics-reports-positive-results-for-novel-cooling-device-to-treat-chronic-ocular-surface-pain 2025-05-14T20:43:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eyecool-therapeutics-reports-positive-results-for-novel-cooling-device-to-treat-chronic-ocular-surface-pain 2025-05-14T20:43:04+00:00 hourly 0.9 https://trial.medpath.com/news/ibrutinib-nivolumab-combination-shows-promising-77-8-response-rate-in-relapsed-cns-lymphoma-trial 2025-05-14T20:43:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ibrutinib-nivolumab-combination-shows-promising-77-8-response-rate-in-relapsed-cns-lymphoma-trial 2025-05-14T20:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/ernexa-therapeutics-expands-operations-with-texas-subsidiary-to-advance-ovarian-cancer-cell-therapy 2025-05-14T20:42:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ernexa-therapeutics-expands-operations-with-texas-subsidiary-to-advance-ovarian-cancer-cell-therapy 2025-05-14T20:42:48+00:00 hourly 0.9 https://trial.medpath.com/news/incyte-to-pay-novartis-280m-in-settlement-over-jakafi-royalty-dispute 2025-05-14T20:41:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/incyte-to-pay-novartis-280m-in-settlement-over-jakafi-royalty-dispute 2025-05-14T20:41:34+00:00 hourly 0.9 https://trial.medpath.com/news/bioinvent-s-bi-1808-shows-promising-results-in-phase-2a-ctcl-trial-with-50-response-rate 2025-05-14T20:41:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioinvent-s-bi-1808-shows-promising-results-in-phase-2a-ctcl-trial-with-50-response-rate 2025-05-14T20:41:26+00:00 hourly 0.9 https://trial.medpath.com/news/genmab-to-present-extensive-epcoritamab-clinical-data-at-2025-european-hematology-association-congress 2025-05-14T20:15:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genmab-to-present-extensive-epcoritamab-clinical-data-at-2025-european-hematology-association-congress 2025-05-14T20:15:07+00:00 hourly 0.9 https://trial.medpath.com/news/elective-nodal-radiotherapy-shows-superior-metastasis-free-survival-in-oligorecurrent-prostate-cancer 2025-05-14T20:15:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elective-nodal-radiotherapy-shows-superior-metastasis-free-survival-in-oligorecurrent-prostate-cancer 2025-05-14T20:15:02+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-belzutifan-as-first-oral-treatment-for-advanced-pheochromocytoma-and-paraganglioma 2025-05-14T20:13:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-belzutifan-as-first-oral-treatment-for-advanced-pheochromocytoma-and-paraganglioma 2025-05-14T20:13:47+00:00 hourly 0.9 https://trial.medpath.com/news/us-orphan-drug-market-set-to-exceed-190-billion-by-2030-as-fda-designations-accelerate 2025-05-14T20:13:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/us-orphan-drug-market-set-to-exceed-190-billion-by-2030-as-fda-designations-accelerate 2025-05-14T20:13:34+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-first-successful-stem-cell-transplant-using-deceased-donor-for-blood-cancer-treatment 2025-05-14T20:13:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-first-successful-stem-cell-transplant-using-deceased-donor-for-blood-cancer-treatment 2025-05-14T20:13:11+00:00 hourly 0.9 https://trial.medpath.com/news/novel-aav-capsid-shows-unprecedented-brain-transduction-potential-for-gene-therapy 2025-05-14T19:46:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-aav-capsid-shows-unprecedented-brain-transduction-potential-for-gene-therapy 2025-05-14T19:46:42+00:00 hourly 0.9 https://trial.medpath.com/news/merck-kgaa-joins-peregrine-ventures-incentive-incubator-as-strategic-partner 2025-05-14T19:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-kgaa-joins-peregrine-ventures-incentive-incubator-as-strategic-partner 2025-05-14T19:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-and-novartis-complete-16-billion-asset-swap-deal-reshaping-both-companies-strategic-focus 2025-05-14T19:32:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-and-novartis-complete-16-billion-asset-swap-deal-reshaping-both-companies-strategic-focus 2025-05-14T19:32:56+00:00 hourly 0.9 https://trial.medpath.com/news/ispe-celebrates-20th-anniversary-with-announcement-of-2025-facility-of-the-year-awards-winners 2025-05-14T18:42:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ispe-celebrates-20th-anniversary-with-announcement-of-2025-facility-of-the-year-awards-winners 2025-05-14T18:42:07+00:00 hourly 0.9 https://trial.medpath.com/news/arcellx-s-anito-cel-shows-97-response-rate-in-pivotal-multiple-myeloma-trial 2025-05-14T17:05:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arcellx-s-anito-cel-shows-97-response-rate-in-pivotal-multiple-myeloma-trial 2025-05-14T17:05:51+00:00 hourly 0.9 https://trial.medpath.com/news/surrozen-secures-key-patent-for-antibody-based-wnt-pathway-modulators-with-potential-in-retinal-disease-treatment 2025-05-14T16:45:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/surrozen-secures-key-patent-for-antibody-based-wnt-pathway-modulators-with-potential-in-retinal-disease-treatment 2025-05-14T16:45:17+00:00 hourly 0.9 https://trial.medpath.com/news/bruker-and-10x-genomics-end-patent-disputes-with-global-settlement-and-cross-license-agreements 2025-05-14T16:45:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bruker-and-10x-genomics-end-patent-disputes-with-global-settlement-and-cross-license-agreements 2025-05-14T16:45:12+00:00 hourly 0.9 https://trial.medpath.com/news/autolus-reports-promising-long-term-data-for-obe-cel-in-relapsed-refractory-b-all-at-eha-congress 2025-05-14T16:45:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/autolus-reports-promising-long-term-data-for-obe-cel-in-relapsed-refractory-b-all-at-eha-congress 2025-05-14T16:45:06+00:00 hourly 0.9 https://trial.medpath.com/news/five-promising-therapeutic-candidates-in-parkinson-s-disease-clinical-pipeline 2025-05-14T16:43:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/five-promising-therapeutic-candidates-in-parkinson-s-disease-clinical-pipeline 2025-05-14T16:43:10+00:00 hourly 0.9 https://trial.medpath.com/news/thiogenesis-launches-phase-2-trial-of-tti-0102-for-melas-a-rare-mitochondrial-disease 2025-05-14T16:43:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thiogenesis-launches-phase-2-trial-of-tti-0102-for-melas-a-rare-mitochondrial-disease 2025-05-14T16:43:03+00:00 hourly 0.9 https://trial.medpath.com/news/novel-treatment-regimen-extends-myeloma-remission-by-seven-months-in-uk-clinical-trial 2025-05-14T16:42:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-treatment-regimen-extends-myeloma-remission-by-seven-months-in-uk-clinical-trial 2025-05-14T16:42:58+00:00 hourly 0.9 https://trial.medpath.com/news/atossa-s-z-endoxifen-shows-77-7-tumor-reduction-in-phase-2-breast-cancer-trial 2025-05-14T16:42:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atossa-s-z-endoxifen-shows-77-7-tumor-reduction-in-phase-2-breast-cancer-trial 2025-05-14T16:42:56+00:00 hourly 0.9 https://trial.medpath.com/news/forge-biologics-partners-with-fractyl-health-to-manufacture-aav-for-novel-pancreatic-gene-therapy-targeting-obesity-and-type-2-diabetes 2025-05-14T16:42:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/forge-biologics-partners-with-fractyl-health-to-manufacture-aav-for-novel-pancreatic-gene-therapy-targeting-obesity-and-type-2-diabetes 2025-05-14T16:42:33+00:00 hourly 0.9 https://trial.medpath.com/news/novel-gene-editing-therapy-shows-promise-for-rare-fatal-heart-disease-attr-cm 2025-05-14T16:41:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-gene-editing-therapy-shows-promise-for-rare-fatal-heart-disease-attr-cm 2025-05-14T16:41:53+00:00 hourly 0.9 https://trial.medpath.com/news/therini-bio-secures-39m-in-series-a-extension-to-advance-novel-fibrin-targeting-therapy-for-neurodegenerative-diseases 2025-05-14T16:41:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/therini-bio-secures-39m-in-series-a-extension-to-advance-novel-fibrin-targeting-therapy-for-neurodegenerative-diseases 2025-05-14T16:41:46+00:00 hourly 0.9 https://trial.medpath.com/news/invivyd-challenges-fda-with-citizen-petition-to-prioritize-monoclonal-antibodies-for-covid-19-prevention 2025-05-14T16:41:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/invivyd-challenges-fda-with-citizen-petition-to-prioritize-monoclonal-antibodies-for-covid-19-prevention 2025-05-14T16:41:43+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-in-targeted-drug-delivery-novel-bacteriophage-loaded-wound-dressings-show-promise-for-chronic-infections 2025-05-14T16:41:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-in-targeted-drug-delivery-novel-bacteriophage-loaded-wound-dressings-show-promise-for-chronic-infections 2025-05-14T16:41:16+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-and-adarx-form-335-million-collaboration-to-develop-next-generation-sirna-therapies 2025-05-14T16:41:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-and-adarx-form-335-million-collaboration-to-develop-next-generation-sirna-therapies 2025-05-14T16:41:15+00:00 hourly 0.9 https://trial.medpath.com/news/iteos-and-gsk-halt-development-of-tigit-antibody-belrestotug-after-phase-ii-trial-failures-in-lung-and-head-neck-cancers 2025-05-14T16:11:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iteos-and-gsk-halt-development-of-tigit-antibody-belrestotug-after-phase-ii-trial-failures-in-lung-and-head-neck-cancers 2025-05-14T16:11:29+00:00 hourly 0.9 https://trial.medpath.com/news/renovaro-launches-augusta-ai-powered-platform-aims-to-transform-neurological-drug-discovery 2025-05-14T16:09:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/renovaro-launches-augusta-ai-powered-platform-aims-to-transform-neurological-drug-discovery 2025-05-14T16:09:56+00:00 hourly 0.9 https://trial.medpath.com/news/betterlife-pharma-s-betr-001-shows-promise-as-non-hallucinogenic-neuroplastogen-for-psychiatric-disorders 2025-05-14T16:09:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/betterlife-pharma-s-betr-001-shows-promise-as-non-hallucinogenic-neuroplastogen-for-psychiatric-disorders 2025-05-14T16:09:54+00:00 hourly 0.9 https://trial.medpath.com/news/channel-therapeutics-nav1-7-inhibitor-shows-promising-results-for-ocular-pain-in-preclinical-trials 2025-05-14T16:09:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/channel-therapeutics-nav1-7-inhibitor-shows-promising-results-for-ocular-pain-in-preclinical-trials 2025-05-14T16:09:53+00:00 hourly 0.9 https://trial.medpath.com/news/philips-and-polarean-expand-radiation-free-xenon-mri-technology-for-pediatric-lung-disease 2025-05-14T16:08:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/philips-and-polarean-expand-radiation-free-xenon-mri-technology-for-pediatric-lung-disease 2025-05-14T16:08:35+00:00 hourly 0.9 https://trial.medpath.com/news/first-generic-eltrombopag-launches-expanding-access-for-thrombocytopenia-and-aplastic-anemia-patients 2025-05-14T16:08:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-generic-eltrombopag-launches-expanding-access-for-thrombocytopenia-and-aplastic-anemia-patients 2025-05-14T16:08:34+00:00 hourly 0.9 https://trial.medpath.com/news/precision-medicine-breakthrough-shows-2-6-fold-survival-improvement-in-deadly-canine-cancer 2025-05-14T16:07:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/precision-medicine-breakthrough-shows-2-6-fold-survival-improvement-in-deadly-canine-cancer 2025-05-14T16:07:35+00:00 hourly 0.9 https://trial.medpath.com/news/exosomes-emerge-as-dual-purpose-tools-in-cancer-from-drug-resistance-mechanisms-to-therapeutic-delivery-systems 2025-05-14T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/exosomes-emerge-as-dual-purpose-tools-in-cancer-from-drug-resistance-mechanisms-to-therapeutic-delivery-systems 2025-05-14T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/brain-organoids-emerge-as-revolutionary-platform-for-alzheimer-s-disease-research-and-digital-twin-development 2025-05-14T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brain-organoids-emerge-as-revolutionary-platform-for-alzheimer-s-disease-research-and-digital-twin-development 2025-05-14T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/national-cancer-centre-singapore-launches-40-clinical-trials-spanning-multiple-cancer-types 2025-05-14T14:23:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/national-cancer-centre-singapore-launches-40-clinical-trials-spanning-multiple-cancer-types 2025-05-14T14:23:00+00:00 hourly 0.9 https://trial.medpath.com/news/caplin-steriles-receives-usfda-approval-for-generic-haloperidol-decanoate-injection 2025-05-14T13:59:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/caplin-steriles-receives-usfda-approval-for-generic-haloperidol-decanoate-injection 2025-05-14T13:59:55+00:00 hourly 0.9 https://trial.medpath.com/news/incyte-settles-280-million-royalty-dispute-with-novartis-over-jakafi 2025-05-14T13:36:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/incyte-settles-280-million-royalty-dispute-with-novartis-over-jakafi 2025-05-14T13:36:51+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-and-septerna-partner-on-2-2-billion-deal-to-develop-oral-obesity-treatments 2025-05-14T13:09:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-and-septerna-partner-on-2-2-billion-deal-to-develop-oral-obesity-treatments 2025-05-14T13:09:19+00:00 hourly 0.9 https://trial.medpath.com/news/trump-administration-suspends-enforcement-of-mental-health-parity-rule-raising-concerns-over-treatment-access 2025-05-14T13:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-administration-suspends-enforcement-of-mental-health-parity-rule-raising-concerns-over-treatment-access 2025-05-14T13:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/arrive-ai-debuts-on-nasdaq-with-autonomous-delivery-technology-for-healthcare-applications 2025-05-14T12:45:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arrive-ai-debuts-on-nasdaq-with-autonomous-delivery-technology-for-healthcare-applications 2025-05-14T12:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/ibl-international-and-grifols-form-strategic-partnership-to-advance-specialty-diagnostics-with-novel-biomarker-panels 2025-05-14T12:38:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ibl-international-and-grifols-form-strategic-partnership-to-advance-specialty-diagnostics-with-novel-biomarker-panels 2025-05-14T12:38:10+00:00 hourly 0.9 https://trial.medpath.com/news/sun-pharma-increases-investment-in-us-based-pharmazz-to-expand-specialty-therapeutics-portfolio 2025-05-14T12:37:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sun-pharma-increases-investment-in-us-based-pharmazz-to-expand-specialty-therapeutics-portfolio 2025-05-14T12:37:42+00:00 hourly 0.9 https://trial.medpath.com/news/kaerus-bioscience-s-ker-0193-receives-fda-orphan-and-rare-pediatric-drug-designations-for-fragile-x-syndrome 2025-05-14T12:37:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kaerus-bioscience-s-ker-0193-receives-fda-orphan-and-rare-pediatric-drug-designations-for-fragile-x-syndrome 2025-05-14T12:37:39+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-acquires-efimosfermin-alfa-from-boston-pharmaceuticals-in-2-billion-deal-for-liver-disease-treatment 2025-05-14T12:10:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-acquires-efimosfermin-alfa-from-boston-pharmaceuticals-in-2-billion-deal-for-liver-disease-treatment 2025-05-14T12:10:53+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-acquires-phase-iii-ready-liver-disease-therapy-in-2-billion-deal 2025-05-14T12:10:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-acquires-phase-iii-ready-liver-disease-therapy-in-2-billion-deal 2025-05-14T12:10:52+00:00 hourly 0.9 https://trial.medpath.com/news/yaqrit-bolsters-leadership-team-to-advance-late-stage-liver-disease-treatments 2025-05-14T12:10:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/yaqrit-bolsters-leadership-team-to-advance-late-stage-liver-disease-treatments 2025-05-14T12:10:31+00:00 hourly 0.9 https://trial.medpath.com/news/cytokinetics-aficamten-shows-positive-results-in-maple-hcm-trial-for-hypertrophic-cardiomyopathy 2025-05-14T12:10:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cytokinetics-aficamten-shows-positive-results-in-maple-hcm-trial-for-hypertrophic-cardiomyopathy 2025-05-14T12:10:26+00:00 hourly 0.9 https://trial.medpath.com/news/excision-biotherapeutics-showcases-promising-crispr-based-therapies-for-hbv-and-hsv-at-asgct-2025 2025-05-14T10:44:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/excision-biotherapeutics-showcases-promising-crispr-based-therapies-for-hbv-and-hsv-at-asgct-2025 2025-05-14T10:44:00+00:00 hourly 0.9 https://trial.medpath.com/news/glucotrack-secures-ethical-approval-for-long-term-clinical-study-of-implantable-blood-glucose-monitor 2025-05-14T09:36:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glucotrack-secures-ethical-approval-for-long-term-clinical-study-of-implantable-blood-glucose-monitor 2025-05-14T09:36:52+00:00 hourly 0.9 https://trial.medpath.com/news/novel-compound-shp1705-targets-circadian-clock-to-combat-aggressive-glioblastoma 2025-05-14T09:13:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-compound-shp1705-targets-circadian-clock-to-combat-aggressive-glioblastoma 2025-05-14T09:13:22+00:00 hourly 0.9 https://trial.medpath.com/news/define-gps-trial-completes-enrollment-potential-paradigm-shift-in-interventional-cardiology 2025-05-14T08:36:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/define-gps-trial-completes-enrollment-potential-paradigm-shift-in-interventional-cardiology 2025-05-14T08:36:08+00:00 hourly 0.9 https://trial.medpath.com/news/genespire-presents-promising-dosing-data-for-first-in-human-gene-therapy-in-methylmalonic-acidemia 2025-05-14T08:35:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genespire-presents-promising-dosing-data-for-first-in-human-gene-therapy-in-methylmalonic-acidemia 2025-05-14T08:35:51+00:00 hourly 0.9 https://trial.medpath.com/news/gujarat-fdca-expands-pharmaceutical-quality-control-with-new-ahmedabad-testing-laboratory 2025-05-14T08:35:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gujarat-fdca-expands-pharmaceutical-quality-control-with-new-ahmedabad-testing-laboratory 2025-05-14T08:35:43+00:00 hourly 0.9 https://trial.medpath.com/news/hansa-biopharma-s-imlifidase-shows-sustained-five-year-outcomes-in-kidney-transplant-recipients 2025-05-14T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hansa-biopharma-s-imlifidase-shows-sustained-five-year-outcomes-in-kidney-transplant-recipients 2025-05-14T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/komodo-health-s-real-world-evidence-platform-powers-31-research-studies-at-ispor-2025 2025-05-14T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/komodo-health-s-real-world-evidence-platform-powers-31-research-studies-at-ispor-2025 2025-05-14T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-freespira-breathing-system-for-teens-with-anxiety-disorders-empr-com 2025-05-14T07:39:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-freespira-breathing-system-for-teens-with-anxiety-disorders-empr-com 2025-05-14T07:39:50+00:00 hourly 0.9 https://trial.medpath.com/news/gc-biopharma-expands-u-s-plasma-collection-network-with-fda-approval-of-calexico-facility 2025-05-14T07:39:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gc-biopharma-expands-u-s-plasma-collection-network-with-fda-approval-of-calexico-facility 2025-05-14T07:39:40+00:00 hourly 0.9 https://trial.medpath.com/news/bharat-biotech-subsidiary-launches-world-s-first-diva-marker-vaccine-for-lumpy-skin-disease 2025-05-14T07:20:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bharat-biotech-subsidiary-launches-world-s-first-diva-marker-vaccine-for-lumpy-skin-disease 2025-05-14T07:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/pico-snpwt-device-reduces-c-section-complications-by-50-and-cuts-healthcare-costs-by-728000-per-1000-patients 2025-05-14T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pico-snpwt-device-reduces-c-section-complications-by-50-and-cuts-healthcare-costs-by-728000-per-1000-patients 2025-05-14T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/aeva-secures-50-million-strategic-investment-for-4d-lidar-technology-expansion 2025-05-14T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aeva-secures-50-million-strategic-investment-for-4d-lidar-technology-expansion 2025-05-14T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-acquires-efimosfermin-for-1-2-billion-to-target-steatotic-liver-disease 2025-05-14T06:39:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-acquires-efimosfermin-for-1-2-billion-to-target-steatotic-liver-disease 2025-05-14T06:39:49+00:00 hourly 0.9 https://trial.medpath.com/news/intron-seeks-partners-to-repurpose-sal200-for-mrsa-nasal-decolonization-in-surgical-patients 2025-05-14T06:39:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intron-seeks-partners-to-repurpose-sal200-for-mrsa-nasal-decolonization-in-surgical-patients 2025-05-14T06:39:30+00:00 hourly 0.9 https://trial.medpath.com/news/beam-therapeutics-to-present-updated-beam-101-data-from-17-sickle-cell-disease-patients-at-eha-2025 2025-05-14T06:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beam-therapeutics-to-present-updated-beam-101-data-from-17-sickle-cell-disease-patients-at-eha-2025 2025-05-14T06:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/titan-sgstm-stapler-shows-significant-reduction-in-post-operative-gerd-following-sleeve-gastrectomy 2025-05-14T06:09:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/titan-sgstm-stapler-shows-significant-reduction-in-post-operative-gerd-following-sleeve-gastrectomy 2025-05-14T06:09:42+00:00 hourly 0.9 https://trial.medpath.com/news/becton-dickinson-files-patent-infringement-lawsuit-against-baxter-over-infusion-pump-technology 2025-05-14T05:41:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/becton-dickinson-files-patent-infringement-lawsuit-against-baxter-over-infusion-pump-technology 2025-05-14T05:41:42+00:00 hourly 0.9 https://trial.medpath.com/news/novo-holdings-invests-in-schott-poonawalla-to-strengthen-injectable-drug-packaging-capabilities-in-india 2025-05-14T04:35:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-holdings-invests-in-schott-poonawalla-to-strengthen-injectable-drug-packaging-capabilities-in-india 2025-05-14T04:35:35+00:00 hourly 0.9 https://trial.medpath.com/news/exelixis-initiates-phase-1-trial-of-xb628-a-novel-bispecific-nk-cell-engager-for-advanced-solid-tumors 2025-05-14T04:35:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/exelixis-initiates-phase-1-trial-of-xb628-a-novel-bispecific-nk-cell-engager-for-advanced-solid-tumors 2025-05-14T04:35:29+00:00 hourly 0.9 https://trial.medpath.com/news/perfluorohexyloctane-shows-unprecedented-rapid-relief-for-dry-eye-disease-in-phase-4-study 2025-05-14T04:34:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/perfluorohexyloctane-shows-unprecedented-rapid-relief-for-dry-eye-disease-in-phase-4-study 2025-05-14T04:34:51+00:00 hourly 0.9 https://trial.medpath.com/news/nexalin-technology-strengthens-scientific-advisory-board-to-accelerate-alzheimer-s-research-with-novel-brain-stimulation-technology 2025-05-14T04:34:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nexalin-technology-strengthens-scientific-advisory-board-to-accelerate-alzheimer-s-research-with-novel-brain-stimulation-technology 2025-05-14T04:34:40+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-phase-2b-trial-for-adipose-derived-stem-cell-therapy-in-crohn-s-disease 2025-05-14T04:11:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-phase-2b-trial-for-adipose-derived-stem-cell-therapy-in-crohn-s-disease 2025-05-14T04:11:56+00:00 hourly 0.9 https://trial.medpath.com/news/adphc-partners-with-astrazeneca-to-combat-copd-in-abu-dhabi 2025-05-14T04:10:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adphc-partners-with-astrazeneca-to-combat-copd-in-abu-dhabi 2025-05-14T04:10:42+00:00 hourly 0.9 https://trial.medpath.com/news/cipla-targets-fy26-growth-with-glp-1-entry-and-peptide-pipeline-despite-revlimid-headwinds 2025-05-14T04:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cipla-targets-fy26-growth-with-glp-1-entry-and-peptide-pipeline-despite-revlimid-headwinds 2025-05-14T04:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/cellfe-and-made-scientific-partner-to-advance-non-viral-gene-editing-for-t-cell-therapies 2025-05-14T03:11:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellfe-and-made-scientific-partner-to-advance-non-viral-gene-editing-for-t-cell-therapies 2025-05-14T03:11:23+00:00 hourly 0.9 https://trial.medpath.com/news/novel-compound-sana-shows-promise-in-phase-1-clinical-trial-for-obesity-treatment-through-unique-thermogenesis-mechanism 2025-05-14T02:41:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-compound-sana-shows-promise-in-phase-1-clinical-trial-for-obesity-treatment-through-unique-thermogenesis-mechanism 2025-05-14T02:41:23+00:00 hourly 0.9 https://trial.medpath.com/news/patient-centered-approaches-key-to-addressing-health-equity-and-disparities-experts-say 2025-05-14T02:41:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/patient-centered-approaches-key-to-addressing-health-equity-and-disparities-experts-say 2025-05-14T02:41:12+00:00 hourly 0.9 https://trial.medpath.com/news/api-appoints-dr-launa-aspeslet-as-chief-translational-officer-to-accelerate-canadian-life-sciences-commercialization 2025-05-14T02:40:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/api-appoints-dr-launa-aspeslet-as-chief-translational-officer-to-accelerate-canadian-life-sciences-commercialization 2025-05-14T02:40:29+00:00 hourly 0.9 https://trial.medpath.com/news/ats-2025-conference-to-showcase-groundbreaking-pulmonary-research-and-patient-centered-initiatives 2025-05-14T02:40:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ats-2025-conference-to-showcase-groundbreaking-pulmonary-research-and-patient-centered-initiatives 2025-05-14T02:40:04+00:00 hourly 0.9 https://trial.medpath.com/news/orchard-therapeutics-lenmeldy-shows-long-term-efficacy-in-treating-metachromatic-leukodystrophy-nejm-study-reveals 2025-05-14T01:41:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orchard-therapeutics-lenmeldy-shows-long-term-efficacy-in-treating-metachromatic-leukodystrophy-nejm-study-reveals 2025-05-14T01:41:51+00:00 hourly 0.9 https://trial.medpath.com/news/hcw-biologics-secures-5-million-in-follow-on-financing-to-advance-immunotherapy-pipeline 2025-05-14T01:41:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hcw-biologics-secures-5-million-in-follow-on-financing-to-advance-immunotherapy-pipeline 2025-05-14T01:41:50+00:00 hourly 0.9 https://trial.medpath.com/news/ensysce-biosciences-secures-patent-for-novel-opioid-use-disorder-treatment-pf9001 2025-05-14T01:14:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ensysce-biosciences-secures-patent-for-novel-opioid-use-disorder-treatment-pf9001 2025-05-14T01:14:05+00:00 hourly 0.9 https://trial.medpath.com/news/altimmune-secures-100-million-credit-facility-to-advance-pemvidutide-development-for-mash-and-alcohol-related-disorders 2025-05-14T01:12:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/altimmune-secures-100-million-credit-facility-to-advance-pemvidutide-development-for-mash-and-alcohol-related-disorders 2025-05-14T01:12:58+00:00 hourly 0.9 https://trial.medpath.com/news/saint-louis-university-launches-phase-1-trial-for-investigational-west-nile-virus-vaccine 2025-05-14T00:37:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/saint-louis-university-launches-phase-1-trial-for-investigational-west-nile-virus-vaccine 2025-05-14T00:37:47+00:00 hourly 0.9 https://trial.medpath.com/news/meiragtx-unveils-breakthrough-gene-therapies-for-obesity-and-neurodegenerative-diseases-at-asgct-2025 2025-05-14T00:37:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/meiragtx-unveils-breakthrough-gene-therapies-for-obesity-and-neurodegenerative-diseases-at-asgct-2025 2025-05-14T00:37:05+00:00 hourly 0.9 https://trial.medpath.com/news/rgenta-therapeutics-unveils-rswitch-technology-for-precise-control-of-gene-therapy-expression 2025-05-14T00:36:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rgenta-therapeutics-unveils-rswitch-technology-for-precise-control-of-gene-therapy-expression 2025-05-14T00:36:39+00:00 hourly 0.9 https://trial.medpath.com/news/azenta-and-form-bio-partner-to-accelerate-aav-gene-therapy-development-with-ai-powered-analysis 2025-05-14T00:36:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/azenta-and-form-bio-partner-to-accelerate-aav-gene-therapy-development-with-ai-powered-analysis 2025-05-14T00:36:38+00:00 hourly 0.9 https://trial.medpath.com/news/circio-presents-enhanced-circvec-gene-therapy-data-showing-distinct-tissue-expression-patterns-at-asgct-2025 2025-05-14T00:36:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/circio-presents-enhanced-circvec-gene-therapy-data-showing-distinct-tissue-expression-patterns-at-asgct-2025 2025-05-14T00:36:34+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-warning-to-mayne-pharma-for-misleading-nextstellis-birth-control-safety-claims 2025-05-14T00:35:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-warning-to-mayne-pharma-for-misleading-nextstellis-birth-control-safety-claims 2025-05-14T00:35:54+00:00 hourly 0.9 https://trial.medpath.com/news/comend-and-odylia-therapeutics-form-strategic-partnership-to-transform-rare-disease-drug-development-through-patient-driven-platform 2025-05-14T00:34:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/comend-and-odylia-therapeutics-form-strategic-partnership-to-transform-rare-disease-drug-development-through-patient-driven-platform 2025-05-14T00:34:40+00:00 hourly 0.9 https://trial.medpath.com/news/avadel-pharmaceuticals-appoints-susan-rodriguez-as-chief-operating-officer-to-drive-lumryz-commercial-expansion 2025-05-14T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avadel-pharmaceuticals-appoints-susan-rodriguez-as-chief-operating-officer-to-drive-lumryz-commercial-expansion 2025-05-14T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/nhia-and-roche-expand-partnership-to-reduce-cancer-treatment-costs-in-nigeria 2025-05-14T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nhia-and-roche-expand-partnership-to-reduce-cancer-treatment-costs-in-nigeria 2025-05-14T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/stairmed-achieves-clinical-milestone-with-invasive-brain-computer-interface-system-in-amputee-patient 2025-05-14T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stairmed-achieves-clinical-milestone-with-invasive-brain-computer-interface-system-in-amputee-patient 2025-05-14T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/nanocarrier-technology-shows-promise-for-alzheimer-s-disease-treatment-by-overcoming-blood-brain-barrier 2025-05-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanocarrier-technology-shows-promise-for-alzheimer-s-disease-treatment-by-overcoming-blood-brain-barrier 2025-05-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ethris-and-lonza-partner-to-develop-room-temperature-stable-mrna-respiratory-vaccines 2025-05-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ethris-and-lonza-partner-to-develop-room-temperature-stable-mrna-respiratory-vaccines 2025-05-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/adial-pharmaceuticals-receives-milestone-payment-as-adovate-launches-phase-1-trial-for-novel-asthma-therapy 2025-05-13T23:09:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adial-pharmaceuticals-receives-milestone-payment-as-adovate-launches-phase-1-trial-for-novel-asthma-therapy 2025-05-13T23:09:35+00:00 hourly 0.9 https://trial.medpath.com/news/stylus-medicine-emerges-with-85m-to-revolutionize-in-vivo-genetic-medicines 2025-05-13T22:39:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stylus-medicine-emerges-with-85m-to-revolutionize-in-vivo-genetic-medicines 2025-05-13T22:39:37+00:00 hourly 0.9 https://trial.medpath.com/news/artiva-s-allonk-cell-therapy-shows-durable-response-in-lymphoma-patients-in-phase-1-2-trial 2025-05-13T22:12:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/artiva-s-allonk-cell-therapy-shows-durable-response-in-lymphoma-patients-in-phase-1-2-trial 2025-05-13T22:12:26+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-confirms-bevacizumab-benefits-limited-to-high-risk-epithelial-ovarian-cancer-patients 2025-05-13T22:12:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-study-confirms-bevacizumab-benefits-limited-to-high-risk-epithelial-ovarian-cancer-patients 2025-05-13T22:12:21+00:00 hourly 0.9 https://trial.medpath.com/news/valinor-discovery-emerges-from-stealth-with-ai-platform-to-simulate-drug-efficacy-before-clinical-trials 2025-05-13T21:43:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/valinor-discovery-emerges-from-stealth-with-ai-platform-to-simulate-drug-efficacy-before-clinical-trials 2025-05-13T21:43:59+00:00 hourly 0.9 https://trial.medpath.com/news/gensco-pharma-acquires-global-rights-to-rizafilm-and-rizaport-for-migraine-treatment 2025-05-13T21:42:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gensco-pharma-acquires-global-rights-to-rizafilm-and-rizaport-for-migraine-treatment 2025-05-13T21:42:11+00:00 hourly 0.9 https://trial.medpath.com/news/pluto-bio-secures-3-6m-to-expand-ai-powered-platform-for-drug-discovery 2025-05-13T21:42:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pluto-bio-secures-3-6m-to-expand-ai-powered-platform-for-drug-discovery 2025-05-13T21:42:07+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-s-azd1390-enters-gbm-agile-trial-for-newly-diagnosed-glioblastoma-patients 2025-05-13T20:40:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-s-azd1390-enters-gbm-agile-trial-for-newly-diagnosed-glioblastoma-patients 2025-05-13T20:40:08+00:00 hourly 0.9 https://trial.medpath.com/news/new-ultrasound-bioprinter-enables-non-invasive-3d-printing-inside-the-body 2025-05-13T20:39:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-ultrasound-bioprinter-enables-non-invasive-3d-printing-inside-the-body 2025-05-13T20:39:33+00:00 hourly 0.9 https://trial.medpath.com/news/anito-cel-shows-promise-as-novel-bcma-targeted-car-t-therapy-for-multiple-myeloma 2025-05-13T20:38:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anito-cel-shows-promise-as-novel-bcma-targeted-car-t-therapy-for-multiple-myeloma 2025-05-13T20:38:56+00:00 hourly 0.9